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A MESSAGE FROM ASCO’S PRESIDENT
The past few years have been incredibly exciting in cancer research and care. Some of the 
advances highlighted in Clinical Cancer Advances 2016 are already improving the lives of 
patients today, and many others provide direction for further research.
Compared with when I started my career in oncology, today we do the unthinkable. We no 
longer treat cancer simply by its type or stage. In the era of precision medicine, we select—
and rule out—treatments based the genomic profile of each patient and the tumor. We 
manage once-debilitating adverse effects to the point that many, if not most, patients can 
continue their daily activities during treatment.
No recent advance has been more transformative than the rise of immunotherapy, 
particularly over this past year, making immunotherapy the American Society of Clinical 
Oncology’s (ASCO’s) Advance of the Year.
The immunotherapy concept is simple: unleash the body’s immune system to attack cancer. 
It has proven extremely difficult, however, to develop treatments that deliver real, consistent 
results. Decades of bold ideas, dedication, and financial investment in research have been 
required to prove immunotherapy’s worth as a treatment for people with an array of different 
cancers.
Until the US Food and Drug Administration approved the first immune checkpoint blocker 
to treat advanced melanoma in 2011, life expectancy for patients with that disease was 
usually measured in months. But new immunotherapies have extended that time to years—
and melanoma was just the tip of the iceberg. In 2015, clinical trials showed that the 
approach holds promise for patients with other hard-to-treat cancers, including advanced 
lung, kidney, bladder, and head and neck cancers and Hodgkin lymphoma.
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Of course, immunotherapy is not the only area of recent progress—far from it. We also 
continue to make tremendous advances in surgery, chemotherapy, radiation therapy, and 
targeted therapy, and we are learning to deploy these approaches in far better ways.
These advances are proof of the importance of our nation’s investments in cancer research. 
In fact, more than 30% of the studies featured in this report were made possible by federal 
funding.
Congress has taken an important step forward in recognizing the vital importance of federal 
research by increasing fiscal year 2016 funding for the National Institutes of Health (NIH) 
and the National Cancer Institute (NCI). This hard-fought victory came after a decade-long 
decline in NIH funding and significant advocacy effort by ASCO and the larger biomedical 
research community.
ASCO calls on Congress to build on this year’s investment and provide robust funding for 
the federal research enterprise moving forward. We believe that is what it will take to 
achieve more of the kinds of advances highlighted in this report.
Although research funding is a key component, it is not the only factor affecting future 
progress against cancer. We also need to better harness technologic opportunities, including 
big data analytics. Several big data initiatives are currently under way, including ASCO’s 
CancerLinQ. By assembling and analyzing data from millions of electronic health records 
and other sources, CancerLinQ will allow us to learn from every individual treated for 
cancer—not just the fewer than 5% of patients who currently participate in clinical trials.
We also need to make sure that the care we provide offers real value to our patients. In June 
2015, ASCO took an important step by publishing a conceptual framework for assessing the 
value of new cancer treatments on the basis of clinical benefits, adverse effects, and cost. 
This framework is a big advance forward in the needed effort to improve the value of 
medical care, and ASCO will remain heavily engaged in this issue.
Clinical Cancer Advances 2016 represents and acknowledges the collective wisdom that has 
made progress against cancer possible. I hope these achievements will inspire all of us to do 
our part to further accelerate the pace of research and discovery to help the millions of 
people who are living with cancer and the millions more who will face a cancer diagnosis in 
their lifetime.
Julie M. Vose, FASCO
President
American Society of Clinical Oncology
EXECUTIVE SUMMARY
In 2015, approximately 1.7 million Americans received a cancer diagnosis.1 In 2030, this 
number will rise to nearly 2.3 million.2 Today, approximately two of three Americans will 
live at least 5 years after being diagnosed with an invasive cancer.3
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In addition, with care that aims to balance effectiveness of treatment alongside the 
importance of quality of life, more patients than ever are not just living longer but able to 
lead full lives. Yet, cancer remains a leading cause of death in the United States, claiming 
approximately 600,000 lives in 2015.1
On a global level, cancer is now one of the world’s most pressing health challenges. Seven 
of every 10 cancer deaths occur in Africa, Asia, and Central and South America. By the year 
2030, these cancer deaths could increase globally by as much as 80%, according to WHO 
estimates.
The scientific community is working hard to avert this grim projection. Clinical research is 
the bedrock of progress against cancer, and discoveries are moving from bench to bedside 
faster than ever. The best example of this in recent years is the explosion of immunotherapy 
approaches for a variety of cancers.
Overall, research progress from one year to the next is incremental, and true breakthroughs 
are rare. Nevertheless, knowledge gathered from any single study can inform further 
research, and cumulative knowledge and progress result in tangible benefits for patients.
This report, “Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer,” 
reviews the recent top advances and emerging trends in clinical cancer research. These 
advances are based on discoveries in cancer biology that are leading to improved cancer 
treatments for patients. Now in its 11th year, this report also highlights policy issues and 
developments that will affect the future of cancer research in the United States and 
determine the pace of progress going forward.
Advance of the Year: Cancer Immunotherapy
Just 5 years ago, the immunotherapy drug ipilimumab was hailed as the first treatment to 
improve the survival of people with advanced melanoma. Today, newer immunotherapies 
directed against programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) 
proteins seem to be as or even more effective, while causing fewer adverse effects. 
Additional studies have suggested that combining immunotherapy agents from these two 
different classes of drugs may provide even more benefit, although the combined regimens 
can be more toxic.
Research reported in 2015 showed that immunotherapies can improve outcomes for other 
difficult-to-treat cancers. Within 3 months of approving the first PD-1 drug for melanoma, 
the US Food and Drug Administration (FDA) expanded its use to treatment of advanced 
lung cancer. This advance has major implications for cancer care, because lung cancer is the 
most common and most deadly malignancy worldwide.
Last year, early reports indicated that the immunotherapy drugs that block PD-1 or PD-L1 
proteins may play a role in the treatment of other cancers, including those that begin in the 
bladder, kidney, liver, and head and neck. These findings revealed potential new options for 
patients with advanced disease, especially those who had exhausted all standard therapy 
options.
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Exciting early signs of success have also been reported with experimental immunotherapy 
strategies for certain blood cancers (acute lymphoblastic leukemia [ALL] and diffuse large 
B-cell lymphoma [DLBCL]) and glioblastoma, the deadliest brain cancer in adults.
This continued wave of success with immunotherapies, which has extended beyond just a 
few tumor types, promises to transform cancer care, thus making it ASCO’s Advance of the 
Year. Just as important, these achievements are sparking more innovation, such as the 
development of approaches that pair immunotherapy with traditional cancer treatments—
chemotherapy, targeted therapy, and radiation therapy. The first clinical studies of such 
combinations are already under way.
Treatment-Resistant Cancers: Precision Medicine Pushes Ahead
Drug resistance is a notorious and far too common problem in cancer therapy. Each time a 
cancer recurs or worsens, it becomes even more difficult to treat. Although most advanced-
stage cancers cannot be cured, having more treatment options to choose from can improve 
both the length and quality of life.
Precision medicine approaches have been making steady gains against cancers that are 
resistant to traditional cancer therapy. The ever-expanding understanding of tumor biology 
provides direction for the development of new therapies. Treatments like targeted therapy are 
increasingly being tailored to the key genetic mutations that drive the growth of particular 
cancers.
In 2015, researchers reported marked gains in overcoming treatment resistance in several 
difficult-to-treat forms of blood, ovarian, lung, and breast cancers. New targeted treatments 
have been shown to keep cancer growth at bay for months to years. In each case, the success 
of newer treatments has stemmed from discoveries of the molecular underpinnings of cancer 
in general and of the mechanisms of drug resistance in particular.
Improving Quality of Life
Maintaining or improving quality of life for patients throughout the cancer continuum is an 
important component of overall cancer care. It is now recognized that maintaining or 
improving quality of life is particularly important for patients with advanced-stage disease; 
therefore, it is especially important to consider the balance of potential benefits and harms of 
various treatment options.
Accumulating clinical trial evidence supports the long-held belief that proper selection of 
treatment for an individual patient on the basis of his or her circumstances can help 
maximize quality of life. For example, recent research has shown that whole-brain 
irradiation for some patients with brain metastases exacerbates cognitive decline without 
extending survival. Meanwhile, another study identified a group of patients who nonetheless 
may benefit from this therapy.
Patients Gain Access to New Cancer Therapies
Between October 2014 and October 2015, the FDA approved 10 new cancer treatments and 
expanded use for 12 previously approved therapies and one device. These approvals will 
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help improve outcomes for people battling a range of difficult-to-treat cancers, including 
melanoma and ovarian, lung, breast, and blood cancers. A new vaccine for the prevention of 
the viral infections that cause cervical and certain other cancers was also approved in 2015.
Federal Funds Support Critical Research
Clinical cancer research in the United States is made possible through funding from both the 
public and private sectors. Federal funding for cancer research has led to significant 
advances in cancer prevention, detection, diagnosis, treatment, and quality of life over the 
last half century.
When it comes to high-risk, pioneering research, federal funding is indispensable. Federally 
funded research also helps answer critical patient care questions that private industry 
research is unlikely to address. More than 14.5 million cancer survivors are alive in the 
United States today,4 largely because of the nation’s commitment to cancer research.
“One of my proudest accomplishments as a member of Congress is helping to 
double NIH’s funding. That happened over a decade ago and since then the NIH’s 
purchasing power has declined significantly. Now we must reignite our nation’s 
investment in medical research. Congress must not preclude scientists from doing 
lifesaving research.”
— Representative Rosa DeLauro (D-CT)
Join Us: Promote Federally Funded Research
ASCO is committed to advocating for sustained federal investment in medical research 
through the National Institutes of Health, which has delivered steady breakthroughs and 
helped improve survival and quality of life for patients with cancer for more than four 
decades. To raise awareness of the payoff of federally backed studies, ASCO has created 
a badge to signify and publicize research that has received federal funding.
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For more information about using the badge, visit www.asco.org/NIHfunding.
This report features examples of notable research successes achieved thanks to funding from 
the US National Institutes of Health (NIH), including:
• A large, nationwide analysis that found remarkable improvements in long-
term childhood cancer survival rates over three decades.
• A large clinical trial that revealed an additional hormone treatment option 
to reduce the risk of new or recurrent breast cancer after ductal carcinoma 
in situ (DCIS).
• An early clinical trial that showed that a combination of two novel targeted 
drugs may slow the growth of a difficult-to-treat form of ovarian cancer.
• A clinical trial that demonstrated that avoiding whole-brain irradiation for 
limited brain metastases helps preserve patient quality of life.
• New evidence confirming that early palliative care not only extends 
patients’ lives but can also benefit caregivers.
Despite the progress made in improving the care of patients with cancer, federal funding for 
cancer research had remained flat for more than a decade and, in fact, had decreased when 
adjusted for inflation. In inflation-adjusted dollars, the NIH budget was 24% lower in 2015 
than it was in 2003 (Fig 1).
Funding Critical to Cancer Research Progress
Statement by American Society of Clinical Oncology President Julie Vose, MD
“Federally funded cancer research has led to remarkable progress in our understanding of 
cancer. It is behind some of the biggest breakthroughs in detection and treatment, and has 
played a major role in our nation’s declining cancer death rates.
But if we are to conquer cancer, we need to invest more as a nation so that we can prepare 
for what lies ahead. Cancer care is set to change more dramatically in the next 20 years 
than it did in the last 50, thanks in part to advances in health information technology and 
a deeper understanding of cancer’s molecular drivers. As biomedical discovery expands, 
we need to be able to answer difficult questions and pursue new research directions.
Progress is hampered not by the lack of ideas but resources. Recent bipartisan support for 
increased funding for the National Institutes of Health is encouraging but not enough. At 
a minimum, ASCO is calling on lawmakers to provide a robust investment in the 
National Institutes of Health and National Cancer Institute to put biomedical research 
back on track.
As oncologists, we owe it to our patients to push the boundaries of what is possible in 
cancer care. Our nation’s commitment to support a strong federally funded US research 
enterprise ensures that we are well-positioned to deliver the care our patients deserve.”
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In December 2015, Congress took an important step forward in recognizing the vital 
importance of federal research funding. The fiscal year 2016 budget contained a 6.6% 
increase for the National Institutes of Health (NIH) bringing their total budget to $32.1 
billion, including $5.2 billion for the National Cancer Institute (NCI).
Call to Action
ASCO is calling on lawmakers to build on this year’s NIH and NCI investment to ensure 
tomorrow’s cures.
Sustained funding of the NIH and the NCI is critical to maintaining the pace of scientific 
discovery, continued progress against cancer, and the development and delivery of new 
cancer therapies for millions of patients, now and into the future.
About Clinical Cancer Advances
ASCO developed this annual report, now in its 11th year, to document the important 
progress being made in clinical cancer research and highlight emerging trends in the field. 
As a whole, this document attests to the current state of the science and envisions future 
directions of cancer research.
ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which 
funds groundbreaking research and programs that make a tangible difference in the lives of 
people with cancer. For ASCO information and resources, visit www.asco.org. Patient-
oriented cancer information is available at www.cancer.net. The content of Clinical Cancer 
Advances was developed under the direction of an 18-person editorial board comprising 
experts in a wide range of oncology subspecialties. The editors reviewed research reports 
published in peer-reviewed scientific and medical journals or presented at major scientific 
meetings over a 1-year period (October 2014 to October 2015).
To be selected for inclusion in Clinical Cancer Advances, a study must improve meaningful 
outcomes for patients, such as overall survival or quality of life, and also have a substantial 
scientific impact on the field of clinical oncology. The advances featured in this report cover 
the full range of clinical research disciplines: prevention, treatment, patient care, and tumor 
biology.
About the American Society of Clinical Oncology
Founded in 1964, ASCO is the world’s leading professional organization representing 
physicians who care for people with cancer. With nearly 40,000 members, ASCO is 
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committed to conquering cancer through research, education, and promotion of the 
highest quality patient care.
Conquer Cancer Foundation
The Conquer Cancer Foundation was created by the world’s foremost cancer physicians 
of ASCO to seek dramatic advances in the prevention, treatment, and cures of all types of 
cancer. Toward the vision of a world free from the fear of cancer, the foundation works to 
conquer cancer by funding breakthrough cancer research and sharing cutting-edge 
knowledge with patients and physicians worldwide and by improving quality of care and 
access to care, enhancing the lives of all who are touched by cancer.
Over 30 years, more than $90 million in funding has been provided through the Conquer 
Cancer Foundation Grants and Awards Program to support clinical and translational 
scientists at all levels of their careers who are working around the globe to address the 
full spectrum of oncology—from prevention through survivorship and end-of-life care. 
Foundation grants have helped researchers launch successful careers and make 
discoveries that benefit patients with cancer.
Several of the studies featured in this year’s Clinical Cancer Advances report were led by 
past Conquer Cancer Foundation grant recipients who have continued their careers in 
oncology research.
ADVANCE OF THE YEAR: CANCER IMMUNOTHERAPY
Although all research achievements highlighted in this report are remarkable, one area 
clearly stands out from the rest: cancer immunotherapy, ASCO’s Advance of the Year. In 
just a few short years, researchers and regulators have moved several different 
immunotherapy strategies from bench to bedside.
From the first astounding successes in advanced melanoma, there is now evidence that 
immunotherapy works against a range of cancers. Even for patients who have exhausted all 
traditional treatments, immunotherapy is able to halt cancer growth, often with only mild 
adverse effects.
Scientists first conceived the idea of manipulating the body’s immune system to attack 
cancer more than a century ago. However, the task proved to be fraught with challenges and 
setbacks. It would take a deeper understanding of both cancer biology and the immune 
system before safe and effective immunotherapy could be delivered to patients.
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As fundamental research on cancer immunotherapy intensified, clinical trials of promising 
approaches followed in quick succession. Two main strategies are now being explored, both 
achieving major success over the past year. The first involves unleashing the body’s natural 
immune response to cancer, and the second helps the immune system find and destroy 
cancer cells.
Immune Checkpoint Inhibitors: Enhancing the Immune Response to Cancer
An overactive immune system can lead to excessive inflammation and development of 
autoimmune disorders. The body uses molecules known as immune checkpoints to control 
the strength and duration of immune responses, minimizing damage to healthy tissue. Some 
tumors produce these same molecules and thereby suppress the immune response to the 
tumor.
Immune checkpoint inhibitors release these tumor-induced brakes on the immune system, 
unleashing it to attack malignant tumors and stop their growth. These treatments are 
showing promising results in many types of cancer, including melanoma and lung cancer.
The first FDA-approved immune checkpoint inhibitor, ipilimumab, blocks the CTLA-4 
molecule on T cells, which leads to a broad enhancement of immune responses, including 
attacks on cancer cells. A range of newer drugs targets a different immune checkpoint 
protein known as PD-1. Those treatments work by preventing cancer cells from attaching to 
the PD-1 protein on immune cells, which leads to an increased antitumor immune response 
and generally fewer adverse effects (Fig 2).
Melanoma Immunotherapy Moves Ahead: Comparing and Combining Treatments
By the end of 2014, three life-extending checkpoint inhibitor immunotherapies were FDA 
approved for the treatment of advanced melanoma: ipilimumab, nivolumab, and 
pembrolizumab. Overall, these new drugs have surpassed the efficacy of traditional 
melanoma treatments. Nevertheless, advanced melanoma remains incurable, although 
prolonged remissions induced by these immunotherapies extend life for multiple years for 
certain patients. In 2015, new studies explored how these three treatments stack up against 
one another and how to maximize their overall benefit—as stand-alone therapies and as 
combination regimens.
Ipilimumab, a CTLA-4 immune checkpoint inhibitor, was the first treatment to extend the 
lives of patients with advanced melanoma. Yet, recent evidence suggests that nivolumab and 
pembrolizumab, both PD-1 checkpoint inhibitors, may be more effective than ipilimumab. 
For example, in a recent phase III study, the 1-year survival rates were 68% and 74% for 
patients treated with pembrolizumab (depending on treatment schedule), compared with 
58% for those who received ipilimumab.5 In addition, pembrolizumab was associated with a 
lower rate of severe adverse effects, such as fatigue, diarrhea, rash, and colon inflammation 
(colitis).
Patients with advanced melanoma that worsens after ipilimumab or ipilimumab and a 
BRAF-mutated melanoma) gained a new treatment option in 2014.6 The FDA granted 
accelerated approval to the PD-1 checkpoint inhibitor nivolumab on the basis of preliminary 
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findings from a phase III trial.7 In this clinical trial, tumors shrunk in 32% of patients treated 
with nivolumab and only in 11% of those who received standard chemotherapy. Longer 
follow-up will be needed to determine if nivolumab extends survival of patients with 
advanced melanoma.
Severe adverse effects of nivolumab included increased pancreatic and liver enzymes (lipase, 
ALT, AST), anemia, and fatigue, whereas chemotherapy was associated with more 
hematologic toxicity, including lower WBC counts (neutropenia, thrombocy-topenia) and 
anemia. Severe treatment-related adverse effects occurred less frequently with nivolumab 
than with chemotherapy.
More broadly, these findings imply that patients whose tumors stopped responding to one 
type of immune checkpoint inhibitor may still benefit from a different checkpoint inhibitor. 
In fact, some experts believe that combining immunotherapies may be the most promising 
strategy for patients with advanced melanoma.
An early-stage clinical trial of an immune checkpoint inhibitor combination showed 
encouraging results.8 Tumor shrinkage rates were nearly six-fold higher (61% v 11%) 
among patients with untreated advanced melanoma who received ipilimumab and nivolumab 
than among those who received ipilimumab and placebo.
The combination treatment controlled tumor growth longer than ipilimumab alone, but the 
rates of severe adverse effects, colitis, diarrhea, and elevated liver enzyme (ALT) levels were 
higher with the immunotherapy combination (54% v 24%). On the basis of these findings, 
the FDA granted accelerated approval to nivolumab in combination with ipilimumab for the 
treatment of patients with advanced melanoma without the BRAF V600 genetic mutation.9
Meanwhile, results from a larger phase III trial of the same immunotherapy combination 
were also reported in 2015.10 The trial included nearly 1,000 patients with advanced 
melanoma who had not previously received cancer treatment. The median time before the 
disease worsened was 11.5 months with ipilimumab and nivolumab, 7 months with 
nivolumab alone, and 3 months with ipilimumab alone.
The rates of adverse effects were consistent with prior studies and were the highest among 
patients who received the immunotherapy combination. Given that the combination 
treatment was associated with the highest rate of severe adverse effects, the researchers also 
sought to determine whether there would be a particular group of patients who could benefit 
from this treatment.
They found that patients with higher levels of the PD-L1 protein in their tumors seemed to 
do as well with nivolumab alone as with the combination, with a median period of 14 
months before the disease became worse. In contrast, patients with low PD-L1 levels in their 
tumors benefited much more from the combination than from nivolumab alone. If validated, 
these findings would provide clinically relevant information for appropriate selection of 
patients who are most likely to benefit, while sparing patients in whom toxicities would not 
be justified.
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Accelerated Approval
The US Food and Drug Administration Accelerated Approval Program allows for earlier 
approval of drugs that treat serious conditions and that fill an unmet medical need on the 
basis of a surrogate or intermediate end point that is reasonably likely to predict clinical 
benefit. After receiving early approval, clinical trials must still be performed to confirm 
the anticipated clinical benefit of the treatment. Approval of a drug may be withdrawn or 
the labeled indication of the drug may be changed if trials fail to confirm clinical benefit 
or do not demonstrate sufficient clinical benefit to justify the risks associated with the 
drug.
New Treatment Paradigm for Lung Cancer
The role of immunotherapy reached beyond melanoma to include patients with lung cancer 
in 2015. Highly promising clinical trials explored the role of immunotherapy using agents 
directed toward the PD-1 or PD-L1 immune checkpoint proteins. In addition, physicians 
gained new insight into which patients may benefit most from these drugs.
Lung cancer is the most common malignancy worldwide and the leading cause of cancer-
related death, taking 1.6 million lives each year (according to WHO 2012 estimates). 
Although advanced lung cancer remains incurable, targeted therapies, such as epidermal 
growth factor receptor (EGFR) and anaplastic lymphoma receptor tyrosine kinase (ALK) 
inhibitors, may help control tumor growth. However, only a small proportion of patients 
with tumors that harbor specific genetic abnormalities can benefit from targeted therapies at 
this time.
Non–small-cell lung cancer (NSCLC) is the most common form of lung cancer, accounting 
for 85% of all cases. With modern platinum-based chemotherapy, the median life expectancy 
is only approximately 10 months. For patients whose disease worsens after initial treatment, 
docetaxel chemotherapy offers only a modest improvement in survival.
Moreover, the adverse effects of chemotherapy are too difficult for many patients to bear. 
Growing research evidence suggests that immunotherapy may be able to control advanced 
lung cancer longer, with fewer adverse effects.
In March 2015, the FDA approved nivolumab for the treatment of squamous lung cancer that 
worsens after platinum-based doublet chemotherapy.11 The approval was given on the basis 
of findings from a randomized clinical trial of patients with advanced, squamous NSCLC.12 
The clinical trial reported that compared with standard second-line chemotherapy, 
nivolumab significantly improved the median overall survival (9 months v 6 months), nearly 
doubling the 1-year survival rate (42% v 24%).
Another randomized trial showed that nivolumab can provide a similar benefit to patients 
with advanced nonsquamous NSCLC, the predominant form of the disease.13 Compared 
with standard chemotherapy, the median survival was prolonged with nivolumab (12.2 
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months v 9.4 months). This clinical trial also suggested that patients who had tumors with 
high PD-L1 levels experienced more benefit from nivolumab.
Generally, nivolumab was easier for patients to tolerate than docetaxel, causing fewer 
adverse effects. No new toxicities were reported with nivolumab in the treatment of NSCLC. 
However, rare but serious inflammation involving the lungs (pneumonitis), colon (colitis), 
and kidneys (nephritis) was also reported in this trial. In October 2015, the FDA expanded 
the approved use of nivolumab to treat patients with nonsquamous NSCLC whose disease 
worsened during or after platinum-based chemotherapy.14
Perhaps even more promising than the finding that immune checkpoint inhibitors are active 
for patients with lung cancer are the early results showing that these responses are quite 
durable. For example, in one early clinical trial that included patients with advanced, 
squamous, or nonsquamous NSCLC, the 2- and 3-year survival rates were 42% and 27%, 
respectively, at the dose chosen for further development.15
Treatment with the PD-1 blocking immunotherapy pembrolizumab was associated with a 
median survival of 12 months in another early study of patients with advanced, previously 
treated NSCLC. Overall, tumors shrank in approximately one in five patients, but the rate 
was again much greater in those with high PD-L1 levels, of whom nearly half experienced 
tumor shrinkage.16 This group of patients also lived longer before the cancer worsened. No 
new safety concerns were reported.
In September 2015, the FDA granted accelerated approval to pembrolizumab as a treatment 
of patients with advanced, PD-L1-positive NSCLC that worsens after other treatments.17 
Early reports from ongoing studies have suggested that nivolumab and pembrolizumab may 
also be effective as initial therapies for patients with advanced NSCLC.18,19
A new immune checkpoint inhibitor, atezolizumab, has also shown promising results in the 
treatment of advanced NSCLC. Atezolizumab unleashes the immune response to cancer by 
blocking the PD-L1 protein on tumor cells. In an early study, the median survival among 
patients who received atezolizumab was 12.6 months, compared with 9.7 months among 
those treated with docetaxel chemotherapy.20
As in the other studies, patients with the highest levels of PD-L1 in their tumors and immune 
cells benefited even more. In this group, the median survival was 15.5 months with 
immunotherapy, compared with 11.1 months with docetaxel. In contrast, among patients 
with low PD-L1 levels, atezolizumab did not extend survival compared with docetaxel.
Fewer patients experienced severe treatment-related adverse effects in the atezolizumab 
group compared with the docetaxel group. The most common severe adverse effects related 
to atezolizumab were pneumonia and increased AST levels.
In February 2015, the FDA granted atezolizumab a breakthrough therapy designation for the 
treatment of PD-L1–positive NSCLC that worsens after platinum chemotherapy, and a 
randomized phase III trial for this indication is under way (ClinicalTrials.gov identifier: 
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NCT02486718). Other ongoing phase III clinical trials are exploring atezolizumab in 
combination with chemotherapy.
The therapeutic mechanism of immune checkpoint inhibitors—unleashing immune response 
to cancer—is profoundly different from that of standard treatments for NSCLC. This may 
explain the longer duration of benefit some patients experience from immunotherapy 
compared with chemotherapy or targeted therapy. Unlike other therapies, the effects of 
immunotherapy can persist long after the patient stops treatment. Future research directions 
for lung cancer immunotherapy include evaluating combinations of PD-1 or PD-L1 
inhibitors with chemotherapy, targeted therapy, and other types of immunotherapy.
Breakthrough Therapy Designation
The US Food and Drug Administration (FDA) Breakthrough Therapy Designation serves 
to expedite the development and review of drugs for treating serious or life-threatening 
illnesses where preliminary clinical data suggest the drug may provide a substantial 
improvement in patient outcomes. The designation helps ensure patients gain faster 
access to promising new treatments through FDA approval.
Broadening the Possibilities for Checkpoint Inhibitors
The past year brought early reports suggesting that immune checkpoint inhibitors targeting 
PD-1 and PD-L1 are effective across a range of different cancer types, beyond melanoma 
and lung cancer. A particularly encouraging finding was that immunotherapy was effective 
against many tumors that were resistant to traditional treatments.
Bladder cancer—In the last three decades, there has been little progress in the treatment 
of advanced bladder cancer. Most patients with advanced bladder cancer are older (the 
median age of diagnosis is 73 years), and many suffer from kidney impairment. As a result, 
many patients forgo chemotherapy to avoid its difficult adverse effects. Outcomes are poor 
for patients who cannot tolerate chemotherapy or whose cancer worsens after initial 
chemotherapy.
Findings from an early clinical trial of patients with advanced urothelial bladder cancer 
bring new hope.21 The PD-L1 immune checkpoint inhibitor atezolizumab shrank tumors 
rapidly—within weeks of starting treatment in many study participants. Again, atezolizumab 
was particularly effective for patients who had high PD-L1 levels in their tumors and 
immune cells, with approximately half of these patients experiencing tumor shrinkage. The 
median duration of response was much longer than that typical for chemotherapy.
The most commonly reported treatment-related adverse effects were decreased appetite and 
fatigue. Severe adverse effects, such as weakness (asthenia) and hematologic abnormalities 
(thrombocytopaenia and decreased blood phosphorus), occurred in 4% of patients. On the 
basis of these findings, the FDA granted atezolizumab a breakthrough therapy designation 
for the treatment of PD-L1–positive, advanced bladder cancer in 2014. An ongoing phase III 
trial seeks to compare atezolizumab with standard chemotherapy in patients with advanced 
bladder cancer (ClinicalTrials.gov identifier: NCT02302807).
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Kidney cancer—Advanced kidney cancer is another malignancy in dire need of better 
treatments. The most common type of kidney cancer in adults is called renal cell carcinoma 
(RCC). At the time of diagnosis, nearly one third of patients with RCC already have 
metastatic disease, which is difficult to treat.
The last major advance in kidney cancer care occurred a decade ago, with the introduction of 
targeted therapies for metastatic RCC. Vascular endothelial growth factor (VEGF)–directed 
therapies and inhibitors of the mammalian target of rapamycin (mTOR) extended the median 
survival of patients with this disease from 1 year to nearly 3 years.
Yet, new drugs are needed to further extend survival when kidney cancers worsen despite 
VEGF- and mTOR-targeted therapies. Recent research has suggested that PD-1–directed 
immunotherapy may improve the outlook for at least some of these patients.
In a randomized phase II trial, nivolumab shrank tumors in approximately 20% of patients 
with metastatic clear cell RCC who were previously treated with a VEGF inhibitor.22 One 
striking result was related to the durability of these responses, which lasted more than 22 
months in some patients. The median overall survival extended up to 25 months, roughly 1 
year longer than is typically achieved with targeted therapies, as reported in prior clinical 
trials of patients with advanced RCC. Fatigue was the most common treatment-related 
adverse effect.
Meanwhile, larger ongoing trials are exploring additional uses of PD-1–directed therapies 
for metastatic RCC. In a phase III study of patients with advanced RCC who were 
previously treated with VEGF inhibitors, nivolumab improved outcomes compared with the 
mTOR inhibitor everolimus.23 The median survival was 25 months with nivolumab versus 
19.6 months with everolimus. The toxicity profile of nivolumab was consistent with prior 
reports. However, compared with everolimus, there were fewer severe treatment-related 
adverse events reported.
Furthermore, although tumors shrank in 25% of patients treated with nivolumab, only 5% of 
those treated with everolimus experienced tumor shrinkage. Interestingly, however, 
everolimus delayed tumor growth for a similar length of time as nivolumab, approximately 4 
months.
Another ongoing phase III trial is investigating the combination of nivolumab and 
ipilimumab as an initial treatment of advanced kidney cancer (ClinicalTrials.gov identifier: 
NCT02231749). The FDA approved nivolumab for the treatment of RCC in November 
2015.24
Liver cancer—Liver cancer is the second most common cause of death resulting from 
cancer worldwide, claiming approximately 750,000 lives each year.25 The most common 
type of liver cancer is hepatocellular carcinoma (HCC). The only FDA-approved treatment 
of advanced HCC, sorafenib, extends survival by merely 3 months.
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Last year, researchers reported preliminary findings showing a promising role for nivolumab 
in the treatment of metastatic HCC.26 In the small study, nearly 20% of patients had marked 
tumor shrinkage in response to nivolumab. Tumors completely disappeared in two patients.
The responses were durable, lasting 9 months or longer in nearly all patients who responded. 
At 1 year, 62% of patients treated with nivolumab were still alive. This is a dramatic 
improvement when compared with the historical tumor response rate for sorafenib of only 
2% to 3% and 1-year survival rate of 30%. Again, no new safety signals were reported. Of 
note, severe adverse effects of nivolumab included elevated ALT, AST, and lipase levels.
These early findings suggest that immunotherapy may be an effective treatment of some 
patients with advanced liver cancer. An expansion phase of this study, which seeks to recruit 
400 patients, is projected to be completed in 2018 (ClinicalTrials.gov identifier: 
NCT01658878).
Head and neck cancer (HNC)—People with recurrent or metastatic HNC have a poor 
prognosis. With existing treatments—chemotherapy and the targeted drug cetuximab—
survival ranges from 10 to 12 months, on average. Overall, few patients respond to these 
treatments, and adverse effects are significant.
Early findings suggest PD-1 immune checkpoint inhibitors are active in patients with HNC. 
In one small trial, approximately 25% of patients who received the PD-1 immune checkpoint 
inhibitor pembrolizumab experienced tumor shrinkage.27 In contrast, the reported response 
rate to cetuximab was less than 13% in prior clinical trials. Although the toxicity profile of 
pembrolizumab in this population was similar to that in other trials, only 10% of patients 
experienced severe adverse effects, such as swelling of the face and lung inflammation 
(pneumonitis).
Perhaps as important, these agents might be active regardless of whether HNC is associated 
with human papillomavirus (HPV). It is well known that a subgroup of HNCs is HPV-
positive disease, and that these tumors respond better to standard treatment than those that 
are HPV negative. Yet, in the clinical trial discussed here,27 pembrolizumab was active 
across a wide range of patients, including those with HPV-positive and HPV-negative 
tumors.
Although these early data are encouraging, larger studies are needed to determine if 
pembrolizumab can prolong patient survival. Two phase III trials evaluating pembrolizumab 
versus standard treatment in patients with recurrent or metastatic HNC are already under 
way (ClinicalTrials.gov identifiers: NCT02358031 and NCT02252042).
Blood cancer: Hodgkin lymphoma—Hodgkin lymphoma is a cancer of the lymphatic 
system, and it is most common in two age groups: age 15 to 40 years (particularly young 
adults in their 20s) and older than age 55 years. With existing initial treatments, four of five 
patients survive 5 years after a Hodgkin lymphoma diagnosis. People with the disease 
seldom experience recurrence if a complete response is achieved with initial treatment. 
When Hodgkin lymphoma does come back, however, it is more difficult to treat. At that 
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time, patients are typically offered additional chemotherapy, radiation therapy, or stem-cell 
transplantation.
Emerging research data suggest that immunotherapy, specifically PD-1 blockade, may play a 
role in the treatment of recurrent Hodgkin lymphoma. Moreover, it has been speculated that 
a certain genetic abnormality makes Hodgkin lymphoma particularly vulnerable to PD-1 
blockade. Findings from a small clinical trial of adult patients with recurrent Hodgkin 
lymphoma support this hypothesis (this study was funded in part by a grant from the NIH).28
Nearly all the patients in the trial had previously received three or more treatments, 
including stem-cell transplantation and a targeted drug. Remarkably, the great majority (20 
of 23 patients) responded to nivolumab, with cancer completely disappearing in 17%. By 6 
months, only 14% of patients experienced disease progression.
The most common treatment-related adverse effects were rash and decreased platelet count 
(thrombocytopenia). Severe treatment-related adverse effects were rare.
Genetic abnormality tied to better response to PD-1 immunotherapy—Tumors 
with a high number of genetic mutations are likely to trigger a strong immune response, 
because they make more proteins (antigens) that the immune system recognizes as foreign. 
Melanoma, bladder cancer, and lung cancer are among the cancers with the most mutations.
In some patients with other types of cancers, the tumors have large numbers of mutations as 
a result of a genetic abnormality called mismatch repair deficiency, which undermines the 
ability of a cell to repair DNA damage. Scientists have speculated that tumors with this 
abnormality may be susceptible to immune checkpoint blockade.
Mismatch repair deficiency occurs in approximately 15% of colorectal cancers. It is also 
found less frequently in other types of cancer, such as stomach, small bowel, endometrial, 
prostate, and ovarian cancers. The abnormality is sometimes inherited from parents, as is the 
case for patients with Lynch syndrome, but more often, mismatch repair deficiency develops 
at random during a person’s life.
One small trial reported last year provided the first evidence that mismatch repair–deficient 
tumors are susceptible to PD-1 blockade (this study was funded in part by a grant from the 
NIH).29 Four of 10 patients with mismatch repair–deficient colorectal cancer responded to 
treatment with the immune checkpoint inhibitor pembrolizumab (the median progression-
free and overall survival were not reached). In contrast, none of the eight patients with 
colorectal cancers that were not mismatch repair deficient experienced tumor shrinkage; the 
median progression-free survival was 2.2 months.
Furthermore, the researchers found that pembrolizumab was active against other types of 
cancer with mismatch repair deficiency, such as endometrial, ampullary, duodenal, and 
stomach cancers. Five of seven patients responded to pembrolizumab, and the median time 
to disease progression was 5.4 months.
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Policy Focus
Expanding Cancer Research to Include More Older Adults
More than 60% of cancers in the United States occur in people age 65 years and older, a 
population that will grow exponentially over the coming years. Yet, the evidence base for 
treating older adults with cancer is sparse, because they are underrepresented in clinical 
trials, and trials designed specifically for older adults are rare.
In 2015, ASCO issued a policy statement that calls for federal agencies and the cancer 
research community to broaden clinical trials to include older adults and made five 
overarching recommendations:
• Use clinical trials to improve the evidence base for treating older 
adults.
• Leverage research designs and infrastructure to improve the evidence 
base for treating older adults.
• Increase US Food and Drug Administration authority to incentivize and 
require research on older adults with cancer.
• Increase clinicians’ recruitment of older adults with cancer to clinical 
trials.
• Use journal policies to incentivize researchers to consistently report on 
the age distribution and health risk profiles of research participants.
Read the statement at http://jco.ascopubs.org/lookup/doi/10.1200/JCO.2015.63.0319.
The toxicity profile of pembrolizumab was similar to that in other trial reports. Severe 
adverse effects, such as low serum protein levels (hypoalbuminemia), low blood cell counts 
(anemia and lymphopenia), and bowel obstruction, occurred in 41% of patients.
Although this study was small, it opens the possibility of a new treatment option for patients 
with advanced cancer who have tumors with mismatch repair deficiency. More broadly, it 
shows that evaluation of the tumor genome can help identify patients who benefit from 
immunotherapy, regardless of the type of tumor they have. It is already suspected that 
cancers with other DNA repair deficiencies might also be sensitive to PD-1 blockade.
Novel Immunotherapy Approaches Boost the Immune System
T-cell therapies promising for blood cancers—In addition to immune checkpoint 
inhibitors, researchers are exploring other immunotherapy approaches, all of which are 
centered on T cells. A unique new immunotherapy, the antibody blinatumomab, attaches to 
two different proteins on WBCs: CD19 on B cells and CD3 on T cells. By doing so, the 
antibody brings the cancer-killing T cells into contact with the malignant B-cell leukemia 
cells.
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In an early-stage trial, nearly one third of patients with relapsed or treatment-resistant ALL 
had no evidence of cancer (complete remission) after receiving blinatumomab.30 The 
responses were durable, lasting more than 6 months in many patients.
The study participants had an uncommon but aggressive type of ALL known as Philadelphia 
chromosome–negative precursor B-cell ALL, a rapidly growing cancer in which the bone 
marrow makes too many immature WBCs. On the basis of these results, in December 2014, 
the FDA approved blinatumomab to treat this difficult disease.31
Although more research is needed to determine whether blinatumomab can improve survival 
compared with standard chemotherapy, it seems that immunotherapy will play a role in the 
treatment of ALL. Future directions include exploring use of blinatumomab earlier in the 
course of the disease and in combination with other therapies.
Another unique new strategy is the so-called chimeric antigen receptor (CAR) T-cell 
therapy. This approach involves collecting T cells from a patient, genetically reprogramming 
them in the laboratory, and infusing them back into the patient. The reprogrammed T cells 
make specific proteins that enable them to find and attack cancer cells throughout the body.
Early reports have suggested that patients with various difficult-to-treat blood cancers might 
benefit from CAR T-cell therapy. For example, CD19-directed CAR T cells are programmed 
to attack malignant B cells that have the CD19 molecule on their surface.
In a study of adults and children with relapsed ALL, 27 of 30 patients achieved complete 
remission after receiving this novel therapy, and for some (19 of 30), the remissions were 
durable, lasting as long as 2 years (this study was funded in part by a grant from the NIH).32 
Overall, 78% of patients were alive 6 months after receiving CAR T cells.
In another early study, 12 of 15 patients with chemotherapy-resistant DLBCL and other 
blood cancers responded to CD-19 directed CAR T cells, with cancer completely 
disappearing in eight of the patients (this study was funded in part by a grant from the 
NIH).33
Although these findings are promising and support further research, the studies were small 
and limited to patients with hard-to-treat cancers. It is not yet clear if CAR T-cell therapy 
will have broader use in the future. In addition, because CAR T-cell therapy can cause 
considerable toxicities, such as fever (pyrexia), low blood pressure (hypotension), delirium, 
and neurologic adverse effects, it is administered only in specialized clinical centers at this 
time.
Cancer vaccines: A potential new treatment option for brain cancer—
Glioblastoma is an aggressive and incurable form of brain cancer. Most patients are 
diagnosed when the disease is already at an advanced stage. Although surgery and 
chemotherapy can be effective initially, the cancer inevitably worsens over time. After a 
relapse, few treatment options remain, and the average survival duration is only 1.5 years.
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Researchers have been exploring several new avenues for treating brain cancer, including 
immunotherapy strategies, such as vaccines, which deliver substances that trigger a specific 
immune response. Unlike prevention vaccines such as the HPV vaccine, the goal of 
therapeutic cancer vaccines is not to prevent cancer but to help the immune system find and 
attack it.
Preliminary findings from a phase II trial indicate that therapeutic cancer vaccines can 
improve outcomes for patients with relapsed glioblastoma.34 The rindopepimut vaccine 
works against glioblastoma tumors with a specific genetic mutation known as EGFRvIII, 
which contributes to uncontrolled growth of brain tumors. The mutation occurs in 
approximately one in four glioblastomas. It does not occur in healthy brain tissue.
In the study, patients with recurrent glioblastoma who received the vaccine along with the 
targeted drug bevacizumab developed an immune response to the cancer. Compared with 
patients who received bevacizumab alone, those who also received the vaccine experienced 
greater tumor shrinkage and a longer time before disease worsening. The median survival in 
the vaccine group was 12 months compared with 8.8 months in the bevacizumab-alone 
group. The most common toxicity of rindopepimut was a mild injection site reaction.
Policy Focus
21st Century Cures Act
After more than a year of hearings, roundtables, and discussion drafts that included active 
engagement and comments from ASCO, the US House of Representatives passed the 
21st Century Cures Act (H.R. 6) with a strong bipartisan vote. If passed by the Senate 
and signed into law, the bill will accelerate the discovery, development, and delivery of 
promising new treatments to people living with cancer.
The 21st Century Cures Act advances big data and precision medicine by encouraging 
the interoperability of electronic health records and prohibiting practices that prevent data 
sharing, which is key for optimal patient care. The bill also strengthens the National 
Institutes of Health and US Food and Drug Administration by increasing funding for 
federal research that has been and will continue to be crucial for making progress against 
cancer.
In early 2015, the FDA granted rindopepimut breakthrough therapy designation for 
EGFRvIII-positive glioblastoma. A phase III trial of rindopepimut in patients newly 
diagnosed with this type of glioblastoma is under way (ClinicalTrials.gov identifier: 
NCT01480479). Meanwhile, several ongoing, early-stage clinical trials are exploring other 
vaccines for glioblastoma. Cancer vaccines are also being explored as treatments for a range 
of other cancers, including breast, lung, bladder, cervical, kidney, pancreatic, prostate, and 
blood cancers.
“The 21st Century Cures is the promise of the future. This initiative will provide 
the next generation of doctors with powerful tools that will alleviate human 
suffering—and flght cancer—on a scale never before known.”
—Representative Michael C. Burgess, MD (R-TX)
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Continuing Immunotherapy Research
Altogether, the rapid succession of immunotherapy research advances heralds a new pillar of 
cancer treatment beyond the traditional staples of chemotherapy, radiation therapy, and 
surgery. Compared with chemotherapy and targeted therapy, immunotherapy has the 
potential to control tumor growth much longer and often with fewer adverse effects.
It seems reasonable that harnessing a patient’s own immune system to fight cancer would be 
universally effective. In many studies thus far, however, only a minority of patients have 
benefited from immunotherapy approaches. With initial immunotherapies proving effective 
for some patients, researchers are now exploring ways to improve outcomes for more 
patients. These include combining different immunotherapies, using immunotherapy in 
combination with other traditional treatments, and starting immunotherapy earlier in the 
course of the disease.
Researchers are also studying ways to reliably predict response to immunotherapy, so 
patients can be spared the adverse effects and costs of treatments that may not help them. In 
addition, longer follow-up of patients who have received immunotherapies in clinical trials 
will help assess the true clinical benefit of these approaches.
ADVANCES IN CANCER PREVENTION
From genes to lifestyle and environment, many different factors can lead to the development 
of cancer. Worldwide, chronic infections cause approximately 2 million new cancer cases 
each year.35 Among the four main cancer-causing pathogens is HPV, the virus that causes 
nearly all cervical cancers. The same virus is also associated with other genital cancers in 
both men and women, as well as a rising number of HNCs.
According to the Centers for Disease Control and Prevention (CDC), genital HPV is the 
most common sexually transmitted virus in the United States, affecting 79 million people. In 
most cases, the immune system fights off the virus within a couple of years. However, if 
HPV persists, it can cause tissue damage that may lead to cervical cancer, as well as other 
cancers. Although there are more than 150 different types of HPV, only approximately 15 
are associated with increased cancer risk.
Preventive vaccines can reduce the risk of HPV infection and development of HPV-related 
cancers. Two of the high-risk types of HPV (HPV-16 and HPV-18) cause approximately 
70% of cervical cancers, and vaccines for these two strains have been available for nearly a 
decade. In 2015, a new preventive vaccine was introduced that protects against additional 
cancer-causing HPV strains, and new research confirmed the positive impact widespread 
HPV vaccination could have on the rates of HPV cancers.
Global Opportunity and Challenge
Cervical cancer is the second most common type of cancer in women worldwide. Routine 
screening through Pap smears and, more recently, HPV DNA tests has dramatically reduced 
cervical cancer rates in Western countries. In low-resource countries, however, large-scale 
routine cervical cancer screening is not feasible, and access to treatment is limited. 
Dizon et al. Page 21
J Clin Oncol. Author manuscript; available in PMC 2016 October 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
According to the CDC, nine of 10 deaths resulting from cervical cancer occur in less 
developed regions of the world.
HPV vaccination may be the best strategy for reducing the global burden of cervical cancer. 
To realize the full potential of HPV vaccines, more eligible persons need to be vaccinated. 
Cultural, educational, and socioeconomic barriers to vaccination will first need to be 
overcome. In addition, worldwide implementation will require more cost-effective vaccines 
in the future.
Promise of HPV Vaccines
To date, the FDA has approved three different HPV vaccines for the prevention of cervical 
cancer: Gardasil, Cervarix and Gardasil 9. Gardasil, introduced in 2006, protects against 
high-risk HPV-16 and HPV-18 and two types of low-risk HPV that cause 90% of genital 
warts. Cervarix, approved in 2009, also protects against HPV-16 and HPV-18. Either vaccine 
can prevent up to 70% of cervical cancers.
In late 2014, the FDA approved Gardasil 9, which protects against nine high-risk HPV types, 
including five that are not addressed by Gardasil or Cervarix.36 By covering these additional 
HPV types, researchers estimate that Gardasil 9 could potentially prevent 90% of cervical 
cancers worldwide.37
Furthermore, a major study published in 2015 found that widespread HPV vaccination with 
Gardasil or Cervarix could prevent as many as 25,000 HPV-related cancers per year in the 
United States alone.38 These include the majority of invasive cervical, anal, oropharyngeal, 
and vaginal cancers, as well as some other genital cancers. The Gardasil 9 vaccine could 
prevent an additional 4,000 cancer cases per year. These estimates, made using US cancer 
registry data and detection rates of HPV types in tumor tissue, will help evaluate the 
effectiveness of future HPV vaccines.
A 2014 immunization survey found that 60% of US adolescent girls and 42% of teen boys 
have started the three-dose HPV vaccine series.38 However, the survey data also indicate that 
the rates of series completion are poor; only 40% of girls and 22% of boys who began HPV 
vaccination received the recommended three doses.
The CDC recommends that all boys and girls age 11 to 12 years receive an HPV vaccine. 
Although the HPV vaccine has been available for a decade, and vaccination coverage is 
improving, HPV vaccination rates in the United States lag behind those of other developed 
countries. Furthermore, HPV vaccination rates are significantly lower than the rates of other 
vaccinations recommended for adolescents (eg, pertussis and meningococcal disease 
vaccines).39
Remaining Questions
Given that none of the available vaccines protect against all high-risk HPV types, routine 
cervical cancer screening is still recommended after HPV vaccination. It is not yet known 
how long the initial series of HPV vaccinations will last or whether booster vaccinations 
might be necessary to maintain ongoing protection.
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Longer follow-up of people who received a vaccine in clinical trials will provide important 
information about the need for reimmunization. It will likely take several more years to 
determine the impact of vaccination on overall incidence of and death rates from HPV-
related cancers. (Appendix Table A1 (online only) lists additional notable advances in cancer 
prevention.
ADVANCES IN CANCER TREATMENT
Research continues to deliver new and improved treatment options for thousands of people 
living with cancer. Between October 1, 2014, and October 15, 2015, the FDA approved 10 
new cancer treatments and a new cancer prevention vaccine (Table 1). These new approvals 
include three immunotherapies (blinatumomab, nivolumab, and dinutuximab) and five novel 
targeted drugs (olaparib, palbociclib, lenvatinib, panobinostat, and sonidegib).
In addition, the FDA expanded the use of 12 previously approved cancer therapies and one 
device. Altogether, the approvals have broadened treatment options for the most common 
cancers, including lung, breast, colorectal, and skin cancers, as well as less common but 
difficult-to-treat illnesses, such as ovarian cancer, multiple myeloma, ALL, and brain cancer.
Besides tremendous success with immunotherapy (as described in Advance of the Year: 
Cancer Immunotherapy), 2015 marked significant advances in using well-established 
approaches to treat cancer: hormone therapy, chemotherapy, and surgery. Such advances will 
help improve outcomes for patients with breast cancer, HNC, rectal cancer, and stomach 
cancer, as well as sarcoma. Researchers have also reported encouraging results using a 
unique new, noninvasive device to treat the most deadly type of brain cancer.
Precision medicine is shaping up to become a mainstream treatment approach for many 
types of cancer. Our understanding of tumor biology and the molecules that make tumors 
grow and spread is rapidly expanding. Building on this knowledge, promising new, targeted 
therapies have emerged for several hard-to-treat forms of blood, ovarian, breast, and kidney 
cancers.
“Just about every person in this country has been touched by cancer and we want to 
make sure that what we do in Congress helps bring better treatments and cures to 
the people who are flghting life-threatening diseases. Clinical cancer research has 
yielded tremendous gains and breakthroughs, but we can’t afford to stop this 
progress. Millions of Americans are counting on us.”
— Representative Gene Green (D-TX)
Novel Treatment Device for Brain Cancer
Glioblastoma is one of the most common and deadliest forms of brain cancer in adults. 
Fewer than 10% of patients survive 5 years after initial diagnosis. Despite initial remission, 
the tumor often grows back and spreads quickly to other areas of the brain.
Preliminary findings from a large clinical trial point to a new possibility to improve 
outcomes for glioblastoma.40 The approach is unlike other treatments for brain or other 
cancers, using so-called tumor-treating fields (TTFs) to stop the growth of rapidly dividing 
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tumor cells. TTFs are low-intensity electrical fields that are delivered through the skin from 
a device patients wear on their head.
In the trial of patients with newly diagnosed glioblastoma who underwent surgery, adding 
TTFs to standard radiation therapy and chemotherapy delayed disease progression by a 
median duration of 3 months. The 2-year survival rate was 43% in the TTF group versus 
29% in the standard therapy group (brain surgery followed by radiation therapy and 
chemotherapy).
The TTF device was previously approved by the FDA for the treatment of recurrent 
glioblastoma, and in 2015, the FDA expanded its use to treat patients with newly diagnosed 
glioblastoma.41,42 Yet, it is unclear how well this new therapy that disrupts cell division will 
be adopted in routine practice. The effect of the device on patient quality of life remains 
controversial, because some patients have reported that wearing the device was too onerous.
Averting Breast Cancer Recurrence
Ovarian suppression helps younger, high-risk patients—Initial treatment of 
estrogen receptor (ER)–positive breast cancer includes surgery followed by radiation therapy 
or chemotherapy. For premenopausal women, additional (adjuvant) treatment with the 
hormone drug tamoxifen is recommended to prevent recurrence—especially in women who 
are at higher risk. Knowing this type of breast cancer is fueled by estrogen, some experts 
surmised that blocking ovarian production of estrogen would further slow tumor growth and 
prolong the time to recurrence of the cancer. Ovarian function can be suppressed chemically, 
surgically, or by irradiation of the ovaries.
In 2015, the researchers’ hypothesis was confirmed when a phase III trial showed that 
ovarian suppression added to adjuvant hormone therapy improved outcomes for 
premenopausal women with a high risk of recurrence (this study was funded in part by a 
grant from the NIH).43 Compared with women with lower risk of recurrence, the study 
participants with higher risk tended to have larger, higher-grade tumors and cancer that had 
spread to the lymph nodes. All high-risk women had previously received chemotherapy.
At 5 years, 78% of the high-risk women who received tamoxifen alone were cancer free. By 
comparison, 82% of those treated with ovarian suppression and tamoxifen and 86% of those 
treated with ovarian suppression and the aromatase inhibitor exemestane were cancer free at 
5 years. As expected, the addition of ovarian suppression contributed to symptoms of 
menopause.
The added benefit of ovarian suppression was particularly prominent among patients 
younger than age 35 years, nearly all of whom had previously received chemotherapy. 
Among these patients, 5-year cancer-free rates improved from 68% with tamoxifen alone to 
79% with tamoxifen and ovarian suppression and to 83% with exemestane and ovarian 
suppression. For women with a lower risk of recurrence who had not previously received 
chemotherapy, outcomes were similar regardless of the type of adjuvant treatment received, 
with more than 95% remaining cancer free at 5 years. These findings support the use of 
adjuvant ovarian suppression with hormone therapy as a standard of care for premenopausal 
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women with hormone receptor–positive breast cancer, particularly if they have high-risk 
disease and have been treated with chemotherapy.
Aromatase inhibitors: An additional option for DCIS—Women with DCIS are at 
increased risk of developing invasive breast cancer. To reduce this risk, physicians 
recommend that women with ER-positive DCIS receive tamoxifen for 5 years after breast-
conservation surgery (lumpectomy).
A nationwide randomized trial reported that the aromatase inhibitor anastrazole may also 
yield excellent outcomes for post-menopausal women (this study was funded in part by a 
grant from the NIH).44 Ten-year breast cancer–free survival rates were higher in the 
anastrazole group than in the tamoxifen group (93% v 89%). This benefit was primarily seen 
in postmenopausal patients age younger than 60 years.
Both tamoxifen and aromatase inhibitors are already being used to prevent recurrences of 
more advanced forms of breast cancer. This is the first study to compare the two treatments 
in postmenopausal women with DCIS.
Importantly, the two hormonal drugs cause different adverse effects. The main adverse effect 
of anastrazole is hastening of osteoporosis, which increases the risk of bone fracture. 
Compared with those receiving tamoxifen, women receiving anastrazole are more likely to 
have joint pain but less likely to have hot flashes or blood clots in the veins. Tamoxifen is 
associated with slightly increased rates of uterine cancer, although this risk is low overall. 
Experts agree that both approaches carry their own risks and benefits and that patients 
should still consider the full range of options, including foregoing adjuvant treatment.
Targeted Therapy
Targeted therapy is designed to target molecules precisely in or on cancer cells or in the 
tissue surrounding a tumor. Genetic changes can cause cells to make too much of a certain 
protein or to produce abnormal proteins. Targeted therapy works by blocking or switching 
off such proteins that cause the cells to keep growing and dividing.
Precision medicine builds on the ever-expanding understanding of tumor biology. Several 
recent advances illustrate how specific molecular vulnerabilities in cancer can be exploited 
to develop powerful new treatments.
In 2015, researchers reported remarkable success with targeted therapy, with a range of new 
treatments that slow the growth of advanced cancers. In addition, early promising results 
were reported on drugs targeting a number of rare genetic abnormalities in lung tumors.
The FDA approved two first-in-class therapies, olaparib for the treatment of advanced 
ovarian cancer and palbociclib for the treatment of advanced breast cancer. Each of these 
drugs blocks a specific molecule that fuels the growth of that cancer.
Scientists also use information on the genetic makeup of different cancers to find new uses 
for existing drugs. For example, the targeted therapy ibrutinib, previously approved for 
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chronic lymphocytic leukemia, was shown to work well against another type of blood cancer 
that shares the same genetic mutation, Waldenström ’s macroglobulinemia (WM).
Similarly, another study confirmed that sorafenib, a drug used to treat liver, kidney, and 
thyroid cancers, is effective against acute myeloid leukemia (AML), as predicted by early 
research on key molecules implicated in this disease. Finally, a drug approved to treat 
thyroid cancer, cabozantinib, was found to delay worsening of advanced kidney cancer and 
NSCLC.
Tumor biology: Aiming at rare targets in lung cancer—Genetic mutations that 
cause cells to make abnormal proteins can lead to cancer. A landmark 2014 study found that 
two thirds of advanced lung adenocarcinomas harbor at least one such cancer-causing 
genetic change.45 This finding is important, because it suggests that most such patients may 
benefit from a targeted treatment that blocks the cancer-fueling protein. Nonetheless, only a 
minority of patients with lung cancer are candidates for targeted therapies at this time.
In the study, the most common genetic abnormalities were KRAS mutation (25%), 
sensitizing EGFR mutations (17%), ALK rearrangements (8%), other EGFR mutations 
(4%), ERBB2 mutations (3%), and BRAF mutations (2%). Several targeted drugs are 
already widely used to treat patients with EGFR mutations in the tumor: afatinib, erlotinib, 
and gefinitib. Crizotinib and ceritinib are recommended for tumors with ALK 
rearrangements. However, development of new options remains critical, because not all 
patients with ALK-positive NSCLC respond to these treatments, and some cannot tolerate 
them. Unfortunately, no treatments are yet available to target the most common genetic 
change: KRAS mutation.
Findings from a recent phase II trial point to a promising new treatment for patients with 
advanced ALK-positive NSCLC that is resistant to crizotinib. A novel ALK inhibitor, 
alectinib, shrank tumors in half of the patients treated in the trial, with a median response 
duration exceeding 11 months.46 The treatment also shrank brain metastases in close to 60% 
of patients. Serious treatment-related adverse effects, such as dyspnea and pulmonary 
embolism, occurred in 27% of patients.
In June 2013, the FDA granted alectinib a breakthrough therapy designation. In 2014, 
alectinib was approved in Japan for the treatment of advanced or recurrent ALK-positive 
NSCLC. In December 2015, the FDA granted accelerated approval to alectinib for the 
treatment of patients with metastatic ALK-positive NSCLC that has worsened after, or who 
could not tolerate, crizotinib.47 However, larger studies are needed to confirm the efficacy of 
alectinib. Meanwhile, many other ALK inhibitors that seem more potent than crizotinib or 
are active in crizotinib-resistant tumors are already in clinical trials.48 Emerging research 
findings suggest that patients with lung cancers driven by uncommon genetic abnormalities 
can also benefit from targeted therapies.
In another early clinical trial, crizotinib shrank tumors of 72% of patients with ROS1 gene 
rearrangements (this study was funded in part by a grant from the NIH).49 The median 
duration of response was more than 17 months. ROS1 rearrangement is found in only 1% of 
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tumors of patients with NSCLC. The most common treatment-related toxicities were visual 
impairment, diarrhea, and nausea. However, nearly all of the reported adverse effects were 
mild.
Approximately 28% of patients with similarly uncommon RET gene rearrangements 
responded to the targeted drug cabozantinib, which was previously approved by the FDA for 
the treatment of thyroid cancer.50 The median time to progression of advanced NSCLC was 
7 months. Toxicities were mostly mild and included fatigue, diarrhea, hand-foot syndrome, 
and low platelets.
Preliminary results from a small trial suggest that the targeted drug dabrafenib is active 
against advanced NSCLCs harboring a specific mutation in the BRAF gene, V600E.51 The 
treatment shrank tumors in 63% of the patients, and treatment-related adverse effects were 
mostly mild. The most common toxicities were fever, diarrhea, nausea, and vomiting. 
Dabrafenib is approved for the treatment of melanoma with the same mutation.
Finally, a large genomic profiling study identified a rare new subgroup of patients with 
NSCLC who could potentially respond to targeted MET inhibitors.52
Although ALK, ROS1, RET, and BRAF mutations are rare in frequency, given the high 
incidence of NSCLC, thousands of people may be candidates for the new targeted therapies. 
Further research is needed to determine the best way to screen patients for rare genetic 
changes. New technologies, such as next-generation sequencing and multiplex testing, may 
help more patients receive treatments targeting mutations in the tumor.
Targeted Agent and Profiling Utilization Registry (TAPUR)
Precision Medicine Trial by the American Society of Clinical Oncology
The TAPUR study, the first-ever clinical trial by ASCO, will use big data by learning 
from the real-world practice of precision medicine. TAPUR will offer patients with 
advanced cancer access to molecularly targeted cancer drugs and collect data on clinical 
outcomes to help learn the best uses of these drugs outside of indications approved by the 
US Food and Drug Administration.
TAPUR is designed to include a broader patient population than is typically enrolled in 
clinical trials. It will accept patients with any advanced solid tumor, multiple myeloma, or 
B-cell non-Hodgkin lymphoma who are no longer responding to standard anticancer 
treatment or for whom no acceptable treatment is available. Patients will be screened to 
determine if they are healthy enough to participate on the basis of broad inclusion and 
exclusion criteria.
If and when a patient meets the defined trial criteria, his or her treating physician will 
select a drug from among those available in the TAPUR study protocol that targets the 
identified genomic variation in the tumor. All patients who receive treatment through 
TAPUR will be monitored for standard toxicity and efficacy outcomes, including tumor 
response, progression-free and overall survival, and duration of treatment.
ASCO plans to begin recruiting patients to participate in TAPUR in early 2016.
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Zeroing in on a blood cancer’s weak spot—WM is a rare, slow-growing type of 
lymphoma. The disease can start almost anywhere in the body and may spread to almost any 
organ. In fact, when WM is diagnosed, it usually involves the blood and the bone marrow.
Patients with WM sometimes have thickened blood, which may cause symptoms such as 
headache, blurry vision, dizziness, and shortness of breath. Treatments include watchful 
waiting, chemotherapy, and monoclonal antibodies. This approach to treatment changed in 
2015 with the approval of a new targeted drug that is effective in the vast majority of patients 
with WM.
In 2012, scientists first reported on a genetic mutation that occurs frequently in patients with 
WM. The abnormality leads to activation of the Bruton’s tyrosine kinase (BTK) protein, 
which drives tumor growth. Less than 3 years later, a small clinical study showed that 
blocking BTK with the targeted drug ibrutinib could be a promising new treatment strategy 
for WM.53
Overall, 90% of patients with previously treated WM responded to ibrutinib, and the 2-year 
survival rate exceeded 95%. These findings led to the FDA approval of ibrutinib for WM in 
January 2015.54 Ibrutinib was previously approved for the treatment of other types of blood 
cancer.
Sorafenib targets AML—Sorafenib is a targeted drug that blocks a range of molecules 
that promote the growth of cancer cells and of the blood vessels to the tumor. It is has been 
FDA approved for the treatment of people with certain types of liver, kidney, and thyroid 
cancers.
Early research suggested that sorafenib may work against AML, because it blocks several 
key molecules implicated in this disease. Preliminary data from the first randomized trial of 
sorafenib in patients with newly diagnosed AML has now confirmed this.55
At 3 years, 56% of patients who received sorafenib and standard chemotherapy and 38% of 
those treated with placebo and standard chemotherapy had not relapsed. The 3-year overall 
survival rates were 63% with sorafenib and chemotherapy and 56% with chemotherapy 
alone. The most common severe treatment-related toxicities included fever and bleeding 
events, both of which occurred more often with sorafenib.
The study was limited to adult patients younger than age 60 years. A prior study in older 
patients with AML showed no benefit of sorafenib. Larger trials are needed to fully assess 
the role of sorafenib in the treatment of people with AML.
Homologous DNA repair: A novel therapeutic target in ovarian cancer—In late 
2014, the FDA approved olaparib for the treatment of advanced serous ovarian cancer with 
BRCA gene mutations.56 This approval marked the first major improvement in the treatment 
of high-grade serous ovarian cancer in 30 years. Serous ovarian cancer is the most common 
type of ovarian cancer, accounting for two thirds of ovarian cancer diagnoses.
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Up to 15% of all ovarian cancers are linked to hereditary mutations in BRCA genes, which 
encode proteins that repair damaged DNA. Olaparib is the first of a new class of DNA repair 
blocking drugs called poly (ADP-ribose) polymerase (PARP) inhibitors. The year 2015 was 
marked by steady advances in research on PARP inhibitors, including new understanding of 
the populations they might benefit, as well as the development of other PARP-targeted 
drugs.
Cancer cells that already have a decreased ability to repair DNA damage because of 
mutations in BRCA1 or BRCA2 genes are particularly vulnerable to PARP inhibitors. These 
drugs completely disable the DNA repair mechanisms of BRCA-mutated cancer cells, 
leading to cell death. Approximately half of high-grade ovarian cancers have other defects in 
the DNA repair machinery of the cells, which may also make them susceptible to PARP 
inhibitors. Healthy cells that do not have an underlying defect in DNA repair are able to 
survive PARP blockade.
Approval of olaparib was given on the basis of a study of women with platinum-sensitive, 
recurrent, serous ovarian cancer.57 Preliminary findings showed that maintenance treatment 
with olaparib delayed disease progression by 7 months compared with placebo. Patients with 
BRCA mutations experienced the most benefit from olaparib, and longer patient follow-up is 
needed to determine if olaparib extends overall survival. Serious treatment-related adverse 
effects, such as fatigue and anemia, were reported in 18% of patients who received olaparib.
The most common adverse effects among patients treated with olaparib were fatigue and 
anemia. Serious adverse effects, such as small intestinal obstruction, were reported in 18% 
of patients who received olaparib and 9% of those who received placebo.
Other recent research has suggested that women who have tumors that become resistant to 
chemotherapy may also benefit from olaparib.58 One study showed that olaparib added to 
chemotherapy slowed cancer progression by roughly 3 months compared with chemotherapy 
alone. Again, the greatest clinical benefit was seen in patients with BRCA mutations. Phase 
III confirmatory trials of olaparib as a maintenance treatment for women with recurrent 
ovarian cancer are under way (ClinicalTrials.gov identifier: NCT01844986).
Ongoing research is also investigating how PARP inhibitors can be used more effectively. 
One study found that adding cediranib to olaparib delayed disease progression of recurrent 
serous ovarian cancer for 8 months longer than olaparib alone (this study was funded by a 
grant from the NIH).59 Women without inherited BRCA mutations particularly benefited 
from the combination. Cediranib is a targeted drug that blocks the growth of blood vessels to 
the tumor. In a previous clinical trial, cediranib administered as maintenance therapy 
improved survival of women with recurrent ovarian cancer.60
Scientists are also working on ways to identify patients who are most likely to benefit from 
PARP inhibitors. For example, it seems that tumors with a mutation in the RAD51C gene, 
which is involved in homologous DNA repair, respond well to another PARP inhibitor, 
rucaparib.61 Like olaparib, rucaparib was active against ovarian tumors with BRCA 
mutations, with 66% of patients experiencing tumor shrinkage.
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Importantly, however, rucaparib was also active against BRCA-negative tumors with 
homologous DNA repair deficiency leading to tumor genome-wide changes, known as loss 
of heterozygosity. Among women with recurrent ovarian cancer treated in a phase II study of 
rucaparib, the population of patients who had loss of heterozygosity also had a treatment 
response rate of 32%. The most common treatment-related adverse effects included GI 
symptoms, fatigue, anemia, and increased liver enzyme (ALT and AST) levels.
In 2015, the FDA granted rucaparib a breakthrough therapy designation to treat women with 
BRCA-positive advanced ovarian cancer. Pivotal studies of rucaparib in women with high-
grade ovarian cancer are under way (ClinicalTrials.gov identifier: NCT01968213). The 
studies will also try to define a molecular signature that might be used to predict which 
patients might benefit from PARP-directed therapies.
Meanwhile, genomic analyses of tumor tissue are revealing additional molecular defects that 
could serve as therapeutic targets in the future. One such study has recently identified genes 
implicated in the resistance of ovarian cancer to chemotherapy.62
Palbociclib sets a new standard of breast cancer care—The year 2015 brought an 
entirely novel treatment option for women with ER-positive breast cancer. This is the most 
common type of breast cancer, accounting for two thirds of cases. ER-positive breast tumors 
need estrogen to grow. Blocking estrogen production or its receptor is the cornerstone of 
ER-positive breast cancer therapy.
In recent years, scientists discovered that proteins called CDK4 and CDK6 also play a 
critical role in ER-positive breast cancer growth. Two large clinical studies subsequently 
showed that blocking CDK4 and CDK6 with the new oral drug palbociclib improved patient 
outcomes.
The first study compared standard hormone therapy letrozole with the combination of 
letrozole and palbociclib in postmenopausal women with advanced ER-positive, human 
epidermal growth factor receptor 2 (HER2)–negative breast cancer.63 The patients had not 
previously received any systemic treatment of the advanced disease.
The median time before the cancer worsened (progression-free survival) was 20 months with 
the palbociclib combination compared to 10 months with letrozole alone. Severe adverse 
effects, such as low WBC levels (neutropenia and leucopenia) and fatigue, were more 
frequently reported among patients who received palbociclib and letrozole.
Severe adverse effects related to the palbociclib and letrozole combination regimen included 
low WBC counts, fatigue, pulmonary embolism, back pain, and diarrhea. In February 2015, 
the FDA granted accelerated approval of palbociclib to be used with letrozole as initial 
therapy for women with ER-positive, HER2–negative breast cancer.64
After initial hormonal therapy stops working for women with advanced breast cancer, the 
next step is typically chemotherapy. Although chemotherapy can be effective, many women 
find the adverse effects too debilitating.
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The second study assessed whether palbociclib could defer the need for chemotherapy.65 
Women with advanced, ER-positive breast cancer that relapsed or worsened after prior 
hormone therapy received palbociclib with the hormone drug fulvestrant or fulvestrant with 
placebo. The median time before the disease worsened was markedly longer with the 
combination treatment (9.2 months) compared with fulvestrant alone (3.8 months). Both 
premenopausal and postmenopausal women benefited from palbociclib. Severe treatment-
related adverse effects, such as low blood cell counts (neutropenia, leukopenia, and 
thrombocytopenia), anemia, and fatigue, were much more common in patients who received 
the combination of palbociclib and fulvestrant.
Together, the findings support the use of palbociclib as part of the standard therapy for ER-
positive advanced breast cancer. More research is needed to determine the impact of 
palbociclib on overall survival and patient quality of life.
Expanding treatment options for advanced kidney cancer—Patients with 
advanced kidney cancer that worsens despite standard therapy are in urgent need of better 
treatment options. Research published in 2015 promises two potential new possibilities: an 
immunotherapy (Advance of the Year: Cancer Immunotherapy) and a targeted drug, both of 
which outperformed the standard second-line treatment, everolimus. The targeted drug 
everolimus blocks a protein called mTOR.
The targeted therapy cabozantinib blocks several different targets in cancer cells, including 
RET, MET, and VEGF receptor 2. The drug was previously approved for the treatment of 
advanced thyroid cancer.
In a large clinical trial of patients with previously treated metastatic kidney cancer, the 
median time before the disease worsened was 7.4 months with cabozantinib versus 3.8 
months with everolimus.66 A preliminary analysis also showed a trend for improved overall 
survival with cabozantinib, but longer patient follow-up is needed to confirm this benefit.
The rates of adverse effects were similar with either drug, although the incidence of severe 
adverse effects was higher with cabozantinib. The most common severe adverse events 
related to cabozantinib were high blood pressure (hypertension), diarrhea, and fatigue, 
whereas anemia, fatigue, and high blood sugar (hyperglycemia) were most common with 
everolimus.
Adjuvant Chemotherapy Extends Survival for Patients With Stomach Cancer
Localized stomach cancer can potentially be cured with surgery, but recurrences are 
common. Approximately four in 10 patients experience a relapse within 2 years of surgery. 
After a relapse, treatment is much more difficult, and survival is shortened.
Recent research has demonstrated that outcomes can be improved if patients receive 
chemotherapy after surgery. A large randomized clinical trial compared postsurgery 
(adjuvant) capecitabine and oxaliplatin chemotherapy with observation.67 The patients had 
stage II to IIIB stomach cancer and had undergone surgical removal of parts of the stomach 
and nearby lymph nodes.
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Adjuvant chemotherapy decreased the risk of cancer recurrence after surgery by 42%. The 
estimated 5-year survival rate was 78% in the chemotherapy group compared with 69% in 
the observation group.
New Treatments for Soft Tissue Sarcoma
Patients with advanced soft tissue sarcoma have poor outcomes, typically surviving 1 year or 
less. If the disease worsens after initial chemotherapy, there are few options available for 
further treatment. Early clinical trial findings point to promising new treatments for two 
common types of soft tissue sarcoma, liposarcomas (fatty tissue) and leiomyosarcoma 
(muscle tissue).
Among patients with treatment-resistant disease, eribulin chemotherapy extended the 
median survival from 11.5 to 13.5 months compared with the standard treatment 
dacarbazine.68 This was the first clinical trial in 20 years to show that a new drug improved 
survival in any type of sarcoma. For a disease where such few treatment options exist, even a 
2-month improvement in survival represents progress. Nevertheless, the survival gain must 
be weighed against the burden of its adverse effects.
Eribulin belongs to a class of anticancer drugs known as microtubule inhibitors, which block 
cell division. The FDA approved eribulin for the treatment of advanced breast cancer in 
2010.
Preliminary findings from another study suggest that the chemotherapy drug trabectedin can 
be effective against treatment-resistant soft tissue sarcoma.69 Compared with dacarbazine, 
trabectedin slowed liposarcoma and leiomyosarcoma progression by a median duration of 10 
weeks. Longer follow-up is needed to determine if there is an improvement in overall 
survival.
The most common toxicities related to trabectedin were GI symptoms, fatigue, headache, 
and tissue swelling. Severe treatment-related adverse effects, including decreased WBC 
(neutrophil) levels and increased ALT levels, were more common with trabectedin than with 
dacarbazine.
The antitumor effects of trabectedin are multipronged: it blocks cell division, transcription of 
genes, and DNA repair. Recently, scientists discovered that trabectedin may also affect the 
tumor microenvironment. In October 2015, the FDA approved trabectedin to treat patients 
with chemotherapy-resistant liposarcoma or leiomyosarcoma that cannot be removed by 
surgery or is advanced.70
Although these survival gains could be construed as minimal, it is important to understand 
that improvements in survival of patients with soft tissue sarcoma have not been achieved 
until now. The hope is that these incremental improvements will provide new opportunities 
for clinical research in this hard-to-treat cancer.
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Interesting Fact
Eribulin and trabectedin are natural products derived from oceanic organisms: the sea 
sponge and the sea squirt, respectively.
Advances in Surgery
For the vast majority of patients today, surgery remains a critical part of cancer care. 
Although it can be lifesaving, surgery also carries the risk of complications, which can 
impair a patient’s quality of life.
Research has delivered new insights that will help physicians and patients decide when it is 
most appropriate to undergo neck lymph node surgery. Until now, research evidence in this 
area was sorely lacking.
Another large clinical trial provided reassurance to patients with rectal cancer considering 
laparoscopic surgery. It showed that this less invasive procedure offers the same survival 
benefit with fewer risks compared with traditional surgery.
Each year, thousands of women with early-stage breast cancer undergo a lumpectomy. For 
such women, a new surgical technique that involves removing a little more tissue during 
lumpectomy may significantly reduce the need for additional surgery after an initial 
lumpectomy.
Neck lymph node removal: When is it necessary?—Cancers that begin in the head 
or neck often spread to lymph nodes in the neck. Physicians commonly recommend 
preventive (elective or planned) neck lymph node surgery to reduce the risk of cancer 
recurrence and spread.
In addition to general risks of anesthesia and surgery, neck lymph node surgery may cause 
damage to the nerves of the lip and tongue, limited neck and shoulder movement, and 
problems talking and swallowing. To avoid such risks, some patients opt to delay lymph 
node removal until their cancer returns or worsens. Recent evidence from two large clinical 
trials will help physicians and patients decide when such surgery is the appropriate choice.
A phase III study conducted in India showed that elective neck lymph node surgery had a 
clear benefit for patients with early oral cancer.71 According to preliminary results, elective 
neck surgery halved the risk of relapse and increased 3-year survival rates by 12%. This new 
evidence will likely encourage greater use of elective lymph node surgery for patients with 
early oral cancer.
Another large clinical trial explored whether patients with more advanced HNC (stage III or 
IV) could forgo planned (elective) neck lymph node surgery after chemotherapy and 
radiation therapy and instead undergo active surveillance with positron emission tomography 
(PET)/computed tomography (CT).72 One group of patients with squamous cell HNC was 
assigned to undergo a planned neck surgery before or after chemotherapy and radiation 
therapy. A second group received chemotherapy and radiation therapy followed by active 
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surveillance with PET/CT imaging. Those patients underwent neck surgery only if the 
PET/CT scan revealed abnormalities.
There was no difference in survival between the two patient groups, but the PET/CT group 
underwent fewer neck surgeries and experienced considerably fewer complications than the 
group who underwent the planned neck surgery. The findings suggest that after 
chemotherapy and radiation therapy, patients with advanced HNC can be safely observed 
using PET/CT. The surveillance approach was also more cost effective compared with 
immediate neck surgery.
Rectal cancer: Laparoscopic surgery outperforms traditional surgery—Patients 
with rectal cancer have two surgical options: laparoscopic surgery or traditional (open) 
surgery. Laparoscopic surgery is performed through several small incisions instead of one 
large incision. A video camera and thin instruments are placed through the incisions to allow 
access to the inside of the body. Laparoscopic procedures are as safe as traditional surgery, 
and recovery time is shorter.
A large clinical trial comparing traditional and laparoscopic rectal cancer surgery concluded 
that the laparoscopic procedure may improve outcomes for some patients.73 The rates of 
local recurrence did not differ between laparoscopy and traditional surgery. However, among 
patients with distal rectal cancer, local recurrences were less frequent after laparoscopy than 
after traditional surgery.
At 3 years, the rate of disease-free survival was 75% in the laparoscopy group and 71% in 
the traditional surgery group. For patients with stage III rectal cancer, however, laparoscopy 
provided a larger improvement in 3-year disease-free survival: the rates were 52% with 
traditional surgery and 65% with laparoscopy. Across disease stages, the two types of 
surgery resulted in similar overall survival rates at 3 years. These findings suggest that 
laparoscopic surgery, when performed by a highly trained colorectal surgeon, is not inferior 
to traditional surgery, at least for some types of rectal cancer.
Lumpectomy: Getting it right the first time—Many women diagnosed with early-
stage breast cancer undergo a lumpectomy. During a lumpectomy, the surgeon removes the 
tumor and a small area of surrounding healthy tissue, which is known as a surgical margin. 
Specimens of the removed tissue are examined under a microscope. If cancer cells are seen 
at or close to the edge of the specimen, it is said to have positive margins. Margins that are 
free of cancer cells are called negative.
Up to 40% of women with early-stage breast cancer have positive margins after 
lumpectomy. In such cases, physicians often recommend a second surgery to remove more 
tissue, because any remaining cancer cells increase the risk of recurrence.
A recent study suggests that the need for such additional surgery could be reduced.74 The 
study explored a new technique called cavity shave, which involves removing additional 
tissue around the tumor during initial lumpectomy to improve the odds of achieving negative 
margins. The new technique decreased the rates of additional breast surgery by half (from 
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21% to 10%), and women perceived no difference in cosmetic outcomes with the new 
approach.
The findings of this study are immediately applicable to a large number of women with 
breast cancer. The new approach will spare them the trauma of an additional procedure and 
allow them to start curative treatments sooner. It may also ultimately reduce the number of 
patients who opt for mastectomy instead of a re-excision surgery, as well as reduce overall 
cost of breast cancer care.
Advances in Radiation Therapy for Early-Stage Breast Cancer
Many women with early-stage breast cancer receive radiation therapy after breast-
conserving surgery (lumpectomy) to reduce the risk of cancer recurrence in the breast and 
nearby tissue. In specific circumstances, such as having a larger tumor or cancer spread in 
many lymph nodes, radiation therapy may also be recommended after mastectomy.
After a lumpectomy, most women receive a type of radiation therapy known as whole-breast 
irradiation. Another type of radiation therapy, regional node irradiation, is only 
recommended to certain women, such as those with cancer that has spread to nearby lymph 
nodes or those who are deemed to be at a higher risk of recurrence. For such patients, 
regional node irradiation has been shown to reduce recurrence and improve survival.
Two large clinical trials published last year explored whether adding regional lymph node 
irradiation to whole-breast irradiation improved outcomes after surgery for women with 
early breast cancer. The findings of both studies suggest that the addition of regional lymph 
node irradiation offers no survival benefit but reduces the risk of recurrence.
The first trial included women with early-stage breast cancer that was either node positive or 
node negative with a high risk of recurrence (this study was funded in part by a grant from 
the NIH).75 After lumpectomy and systemic adjuvant therapy, the women received either 
whole-breast irradiation plus regional nodal irradiation or whole-breast irradiation alone. 
There was no difference in the survival rate at 10 years between the two groups (82.8% v 
81.8%), but the disease-free survival rate was higher in the nodal irradiation group (82% v 
77%).
The second clinical trial assessed adding regional node irradiation to either whole-breast or 
chest-wall irradiation for women who had undergone lumpectomy or mastectomy.76 At 10 
years, the addition of regional node irradiation did not improve overall survival rates but did 
slightly increase disease-free survival rates (72.1% v 69.1%). Breast cancer–related deaths 
were less frequent in the nodal irradiation group (14.4% v 12.5%).
Regional nodal irradiation may increase the risk of treatment complications, such as lung 
inflammation, lymphedema (a condition in which extra lymph fluid builds up in tissues and 
causes swelling), heart disease, and second cancers. More research is needed to identify 
patients who might benefit the most from the combination of whole-breast and regional 
nodal irradiation therapy.
Appendix Table A1 lists additional notable advances in cancer treatment.
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Recent Clinical Practice Guidelines
Each year, research yields new knowledge that helps inform all aspects of cancer care, 
including prevention, detection, diagnosis, treatment, and survivorship. Evidence-based 
clinical practice guidelines help to distill knowledge on a particular topic and provide 
recommended care options to assist clinicians in delivering the best treatment and care to 
each patient.
ASCO develops its clinical practice guidelines through a rigorous systematic review of 
relevant medical literature and clinical interpretation from a multidisciplinary panel of 
content experts and patient representatives. In 2015, ASCO issued new clinical practice 
guidelines, updates, and guideline endorsements on a variety of topics to help inform patient 
care (Table 2). The latest guidelines can be viewed at http://www.instituteforquality.org/
recently-published-asco-guidelines.
ADVANCES IN PATIENT CARE
Physicians treating patients with cancer continuously strive not only to extend their patients’ 
lives but also to improve their well-being. In the case of childhood cancers, intensive 
therapies can eradicate the disease, but many survivors face risks of late effects, such as 
second cancers and heart disease. However, a major study in 2015 indicates that today, much 
fewer survivors are dying as a result of such complications compared with three decades 
ago.
Cancer care is also increasingly focused on the whole patient, which includes meeting the 
patient’s physical, emotional, psychological, and spiritual needs. This is achieved through 
improved communication between physicians and their patients, as well as collaboration 
across physician specialties and with nonphysician practitioners. For all patients, and 
particularly those with advanced or incurable cancer, it is important to ensure that the goals 
of treatment are aligned with patients’ preferences.
Multidisciplinary care teams are now common, and more patients are benefiting from 
palliative care services. New research has confirmed that the earlier patients with advanced 
cancer begin receiving palliative care, the longer they live. In addition, researchers found 
that family caregivers who themselves receive palliative care services early are better able to 
cope with caregiving. Research reported in 2015 has also provided valuable new insights 
into the risks and benefits of a type of radiation therapy for patients with cancer that has 
spread to the brain.
“We all worry about ourselves, family, friends being touched by cancer. When an 
oncologist walks into our offices, we want to hear what you have to say, what we 
can do to ensure high-quality, high-value care for all cancer patients. We can flght 
this flght together.”
— Representative Chuck Fleischmann (R-TN)
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Advances in Childhood Cancer Care
Childhood cancer survivors are living longer—For decades, physicians have strived 
to avoid the paradox in which children survive cancer, only to become sick or die years later 
because of complications from the very treatment that cured them of cancer. Close 
monitoring of late effects has led to changes in therapy for the most common childhood 
cancers.
By carefully reducing treatment intensity, physicians have extended the lifespan of many 
childhood cancer survivors since the 1970s. Cancer cure rates have increased alongside a 
decrease in deaths resulting from complications of cancer treatment, such as second cancers 
and heart and lung diseases.
A recent analysis of roughly 34,000 childhood cancer survivors shows major gains in long-
term survival achieved over three decades (this study was funded by a grant from the 
NIH).77 The study explored mortality rates among 5-year childhood cancer survivors 
diagnosed with cancer between 1970 and 1999.
The rate of death resulting from any cause within 15 years of a cancer diagnosis decreased 
from 12.4% among patients diagnosed in the 1970s to 6% among those diagnosed in the 
1990s. This reduction in mortality was associated with changes in therapy that occurred 
during the same time period, such as decreased use of anthracyclines, alkylating agents, and 
cranial irradiation. This is promising news for the more than 370,000 childhood cancer 
survivors in the United States today.
Transplantation options for children with ALL expanded—Most children with 
ALL can be cured with chemotherapy, but those with high-risk disease require additional 
treatment. Hematopoietic stem-cell transplantation, also called bone marrow transplantation, 
is the standard of care for such high-risk patients.
It is estimated that only 20% to 25% of children who are candidates for stem-cell 
transplantation have matched sibling donors. A match is found when the HLA of one 
sibling’s bone marrow matches that of the other, and there is only a 25% chance that bone 
marrow HLA will match between siblings. Fortunately, the availability of unrelated 
volunteer donors has increased over recent decades.
A new study comparing matched sibling versus unrelated donor transplantation provides 
reassurance for continued use of unrelated donor stem cells.78 The survival of children with 
high-risk ALL was not affected by donor selection. The incidence of relapse was low in both 
groups of patients.
Furthermore, the rates of acute graft-versus-host disease, a serious complication of stem-cell 
transplantation, did not differ between sibling and unrelated donor use. Chronic graft-versus-
host disease occurred more frequently after sibling donor transplantation. However, severe 
infections were more common among children who underwent unrelated-donor 
transplantation. These findings suggest that stem-cell transplantation using a well-matched 
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unrelated donor could be a viable alternative for children with ALL who are at high risk of 
relapse but do not have a matched sibling donor.
Reducing Disparities in the Care of Minorities
Minorities have historically been underrepresented in clinical trials. Despite improvements 
in the two decades since Congress required that research funded by the NIH include 
minorities, only 10% of patients enrolled in clinical trial are minorities.
The participation of adult minorities in cancer clinical trials is still not proportional to the 
overall representation of minorities in the United States. This lack of diversity makes it 
difficult to generalize clinical trial findings to real-world populations.
Barriers to minority participation in clinical research are complex and multifaceted. The 
IMPaCT (Increasing Minority Participation in Clinical Trials) project was the first to use 
patient navigation to address such barriers (this study was funded by a grant from the 
NIH).79
Between 2007 and 2014, more than 400 African American patients with cancer were 
referred to IMPaCT. Patient navigators matching the demographic characteristics of patients 
provided guidance to project participants.
Nearly 80% of the study participants who were eligible for a clinical trial enrolled. Patient 
navigation also improved retention in clinical trials. The trial completion rates were 74% for 
those who used patient navigation support while participating in a clinical trial, compared 
with 34% for those who did not have the support of a patient navigator.
Selecting Care to Preserve Quality of Life
Approximately one in four patients with cancer experiences brain metastases. Lung and 
breast cancers are the two cancers that are most likely to spread to the brain. Generally, 
patients with brain metastases have a short life expectancy, but prognosis can vary 
significantly from patient to patient.
Policy Focus
American Society of Clinical Oncology Continues to Call for Clinical Trial Coverage 
for Medicaid Patients
Medicaid is a major source of insurance coverage for racial and ethnic minorities who are 
underrepresented in clinical trials. Unfortunately, it is the only major insurer in which 
coverage of the routine costs associated with participation in a clinical trial is not 
mandated. Some states have statutes requiring coverage of costs of participation in 
clinical trials for Medicaid enrollees, but the vast majority of Medicaid programs do not 
require this coverage.
ASCO strongly believes that patients with cancer who have Medicaid should not face 
insurance barriers to clinical trial participation. ASCO has issued a policy statement on 
Medicaid reform, with recommendations calling for clinical trial protections for patients 
with cancer with Medicaid coverage. In addition, ASCO has advocated on Capitol Hill on 
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this issue and urged the Centers for Medicare & Medicaid Services to require the 
coverage of routine costs associated with participation in clinical trials for all Medicaid 
enrollees.
The initial treatment of most patients with limited brain metastases is stereotactic 
radiosurgery (SRS). SRS is a type of radiotherapy that aims beams precisely at the area of 
the brain tumor. After SRS, some patients also receive adjuvant whole-brain radiation 
therapy (WBRT).
The use of WBRT in patients with limited brain metastases has been controversial. Although 
WBRT does control tumor growth, it can have detrimental effects on quality of life. 
Preliminary findings from a federally funded study have provided new insights into the 
impact of adjuvant WBRTon cognition (this study was funded by a grant from the NIH).80
Patients with one to three small brain metastases who received WBRT after SRS were more 
likely to experience cognitive decline within the first 3 months than those who received SRS 
alone. Specifically, those who received WBRT had a greater decline in memory and verbal 
communication. There was no significant survival benefit from WBRT, compared with SRS 
alone.
The results strongly suggest it may be preferable to forgo WBRT in favor of SRS, because 
SRS can preserve a patient’s cognitive function as long as possible. Longer-term follow-up 
to assess late neurocognitive effects of WBRT is pending.
Nonetheless, WBRT decreases recurrence of brain metastases, and it is possible that it may 
prolong survival in certain patients. A smaller Japanese study identified one such patient 
group.81 Patients with NSCLC who had one to four brain metastases and a favorable 
prognosis lived 6 months longer when treated with SRS and WBRT compared with SRS 
alone. No such survival advantage was observed among patients with a poor prognosis. 
Larger prospective studies are needed to confirm these findings.
Palliative Care Benefits Extend Beyond the Patient
Palliative care is focused on the relief of suffering throughout the course of a patient’s 
illness, starting from the time of diagnosis. It is a partnership between the patient, medical 
specialists, and the patient’s family, with the goal of improving outcomes for both the patient 
and the family. Benefits of palliative care range from improved quality of life and treatment 
satisfaction to extended survival and reduced overall cost of care.
Unfortunately, many patients do not benefit from the full range of palliative care services, 
because palliative care is often introduced late in the course of cancer treatment. In 2012, 
ASCO recommended concurrent use of palliative care with cancer care early in the course of 
illness for any patient with metastatic cancer and/or high symptom burden.82
The randomized clinical trial Educate, Nurture, Advise, Before Life Ends (ENABLE) III has 
provided new evidence in favor of early palliative care. The study was one of the first to test 
concurrent palliative care interventions for patients and caregivers (this study was funded by 
a grant from the NIH).83
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Researchers compared outcomes of patients with advanced cancer who received palliative 
care consults at the time of diagnosis of advanced cancer versus 3 months later. Although 
there were no differences in quality in life between the two groups, patients who received 
palliative care early lived longer. The 1-year survival rate for those who received early 
palliative care consults was 63%, compared with 48% for those who received delayed 
consults.
The same study also assessed a telephone-based palliative care intervention for the family 
caregivers of the patients who participated (this study was funded by a grant from the 
NIH).84 Because most study participants resided in rural areas, a telephone intervention 
improved access to palliative care services. The intervention began either shortly after the 
patient’s diagnosis or 3 months later. An early intervention was associated with lower 
caregiver depression compared with delayed intervention, and quality of life was comparable 
between the two groups.
Family caregivers are a crucial part of the patient care team. They provide daily assistance 
with symptom relief, emotional and spiritual support, personal care, transportation, and care 
coordination. Coupled with the emotional burden of their loved ones’ suffering, caregivers 
endure considerable strain that can affect their well-being. In fact, prior research has shown 
that a caregiver may experience psychological distress that is greater than the patient’s own.
Because the well-being of caregivers affects the well-being of patients, both parties benefit 
when caregivers receive palliative care. It is apparent that the earlier the palliative care 
services can be introduced to caregivers, the better they will be able to cope with their 
experience in the caregiving role. Future caregiver interventions should be tested in larger 
and more diverse populations.
The mounting evidence for the benefits of early palliative care has also spurred efforts to 
expand the availability of such services to all patients who need them. There are still many 
barriers to achieving this goal, from lack of trained personnel to insufficient funding.
Recent research points to one barrier to awareness and education that may be relatively easy 
to address (this study was funded by a grant from the NIH).85 The study found that some 
physicians are more likely to refer patients with cancer to end-of-life hospice care than 
others. That is, those physicians who had previously referred patients to hospice were 
approximately twice as likely to send other patients to hospice.
Moreover, the characteristics of the treating physicians were stronger predictors of hospice 
enrollment than the patients’ medical status, age, gender, or sex. The findings show that 
more effort is required to ensure that palliative care referrals are driven primarily by the 
alignment of patients’ needs and preferences with the assessment of the treating physicians.
Appendix Table A1 lists additional notable advances in patient care.
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LOOKING TO THE FUTURE
This report documents the incredible strides made in cancer research just in the last year; 
however, there is still much to do. This year, more than half a million people will die as a 
result of cancer in the United States alone, and the rate is much higher in low-resource 
countries. Substantially more research is needed for us to sustain this incredible progress and 
ensure that resulting advances are available to those who need it, both domestically and 
abroad.
ASCO has long-advocated for sustained investment in cancer research that can only happen 
with robust funding for the NIH and NCI, so we do not lose the momentum illustrated in this 
report. ASCO has also initiated a number of programs to deliver these advances to 
underserved populations in the United States and elsewhere.
Cancer: A Growing Challenge
As the world’s population continues to grow, so will the incidence and prevalence of cancer. 
It is estimated that 22 million people will be diagnosed with cancer in 2030, up from 14 
million in 2012.86 The greatest increase in cancer incidence will occur in low-and medium-
resource countries, which are expected to experience the fastest population growth.87
In the United States, the number of new cancer cases is projected to reach 2.3 million per 
year by 2030, a roughly 35% increase from 2015. This increase will be driven mainly by 
changing demographics. By 2030, the number of adults in the United States older than age 
65 years is expected to increase to 72 million (up from 35 million in 2000) as the baby 
boomer generation continues to age.88 Risks for developing certain cancers and survival 
outcomes differ among racial and ethnic groups, and this will also affect cancer incidence 
and mortality rates as the US population continues to become more diverse.
Focus on Prevention
The good news is that up to one third of deaths resulting from cancer could be avoided 
through simple lifestyle choices: maintaining a healthy body weight, increasing fruit and 
vegetable intake, increasing physical activity, and avoiding tobacco and alcohol use.
Quitting smoking is the single most important thing a person can do to lower his or her 
cancer risk. Tobacco is linked to 15 types of cancer and responsible for at least one fifth of 
all deaths resulting from cancer. In addition, smoking rates remain high in many parts of the 
world, despite decreasing in most high-resource countries.
Other forms of tobacco use include cigars or pipes, water-pipes, e-cigarettes, and smokeless 
tobacco, such as chewing tobacco and snuff. None of these choices is a safe substitute for 
cigarette smoking, because each can cause serious health problems, including cancer.
In addition to tobacco, alcohol is one of the few substances that research has consistently 
shown is linked to an increased risk of cancer. Drinking alcohol increases the risk of 
developing liver cancer, HNC, esophageal cancer, colorectal cancer, and stomach cancer.
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In the near future, however, obesity is predicted to replace tobacco as the leading modifiable 
risk factor for cancer. Two thirds of US adults and up to 2.3 billion people worldwide are 
overweight. Endometrial, breast, colon, high-grade prostate, and esophageal cancers, along 
with many others, have been associated with being overweight and obesity. Obesity 
contributes to 20% of all deaths resulting from cancer.
Even after a cancer diagnosis, outcomes can be significantly improved if patients adopt 
healthy behaviors, such as stopping alcohol and tobacco use, engaging in physical activity, 
and achieving and maintaining a healthy body weight.
Another major opportunity for cancer prevention lies in broader use of cancer prevention 
vaccines, namely vaccines for two cancers that are most commonly caused by a virus—the 
hepatitis B virus and HPV. More than half of all liver cancers are caused by hepatitis B virus, 
and nearly all cervical cancers are attributed to HPV. Effective and affordable vaccination 
programs could prevent hundreds of thousands of deaths resulting from cancer worldwide 
each year.87
Changing Cancer Landscape
Some experts predict that demographic shifts in the United States will also affect the rates of 
specific cancers. Although breast, prostate, and lung cancers will remain the top three 
cancers diagnosed, thyroid cancer may replace colorectal cancer as the fourth most common 
cancer by 2030.2
Furthermore, deaths resulting from pancreatic or liver cancer are expected to surpass those 
resulting from breast, prostate, or colorectal cancer, although lung cancer will remain the 
leading cause of death as a result of cancer. With 5-year survival rates of only 6% and 18%, 
patients with pancreatic and liver cancers are in urgent need of better treatments.
Precision Oncology and Immunotherapy
For a growing number of patients with cancer, precision medicine is already part of routine 
care. Molecular characteristics of the tumor are often evaluated at the time of diagnosis, and 
whenever possible, therapy is tailored to the abnormality that drives the growth of a 
particular cancer.
Dozens of targeted drugs are already available, and new therapeutic targets are being 
discovered at a rapid pace. Novel clinical trial designs, such as basket and umbrella trials, 
allow for faster testing of new drugs against particular molecular targets. Clinical trials, such 
as ASCO’s TAPUR and NCI’s MATCH (Molecular Analysis for Therapy Choice), will help 
identify new uses for existing targeted therapies by matching them to the genomic signature 
of the tumors of patients with advanced cancer.
Cancer immunotherapies have already proven effective for patients with a range of difficult-
to-treat cancers, many of whom had exhausted all standard treatment options. 
Immunotherapy also has an added advantage: in many cases, it causes fewer serious adverse 
effects compared with standard therapy. Another unique advantage of immunotherapy is that 
it often continues controlling tumor growth long after a patient stops the treatment.
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To see if patient outcomes could be improved further, researchers are now exploring 
combinations of immunotherapy treatments, as well as combinations of immunotherapies 
and other approaches, such as targeted therapy and chemotherapy. Other ongoing efforts in 
the field include finding biomarkers to predict response to immuno-therapy; developing 
novel, more effective, and safer treatments; and expanding the range of cancer therapeutic 
vaccines. In the near future, cancer immunotherapy may become the fourth pillar of cancer 
treatment, along with chemotherapy, surgery, and radiation therapy.
Learning From Big Data
Emerging health information technologies promise to dramatically reshape the cancer care 
landscape, improving quality and efficiency in every cancer care setting. The technologies 
will use big data, such as electronic medical records and genomic test results, to guide 
personalized treatment decisions for each patient. They will also inform hypotheses for 
further research by aggregating and analyzing the massive body of cancer research data, 
practice experience, and practice guidelines. ASCO’s CancerLinQ is well on its way to 
delivering on this promise, as are other health information technology projects from other 
groups.
Improving Care for Patients, Survivors, and Caregivers
ASCO believes that every patient should receive high-quality, high-value care throughout his 
or her journey with cancer. Genomic technologies make it increasingly possible to match the 
right patients with the right therapy from the start, while sparing other patients the adverse 
effects and costs of ineffective treatments.
By targeting the unique characteristics of malignant cells, precision medicine approaches 
will help minimize collateral damage to healthy tissue. Refinements in treatment regimens 
will help reduce short- and long-term adverse effects of cancer therapies. In addition, 
advances in surgery will allow more patients to experience fewer risks and shorter recovery 
time, and blood tests for circulating tumor cells, cell-free DNA, and other tumor products 
may reduce the need for painful biopsies in the future.
In the coming years, researchers will continue to explore strategies for improving patient 
quality of life, beyond managing physical symptoms. Multidisciplinary care teams that focus 
on caring for the whole patient will likely become more common. Additionally, research will 
continue to identify ways to deliver palliative care services not only for patients but also for 
their caregivers, who share many of the burdens of cancer.
ASCO envisions a world where cancer is prevented or cured, and every survivor is healthy. 
Although the number of people living with cancer will continue to increase, the burden of 
cancer may actually lessen as treatments become more effective, adverse effects become 
fewer, and people with cancer are able to live longer, better, and more productive lives.
Cancer prevention strategies, from lifestyle changes to vaccination programs, could be 
deployed more widely. Other prospects are also within reach: harnessing the power of the 
immune system, expanding the possibilities of precision medicine, and integrating big data 
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into cancer care. Increasing federal funding for research is critically important to continuing 
advances in these areas and to maintaining the pace of progress against cancer.
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Appendix Table A1
Additional Notable Advances From October 2014 to October 2015
Area of Research Study Title Reference
Prevention and screening Oral nicotinamide to reduce actinic cancer: A phase 3 
double-blind randomized controlled trial
Martin A, et al: J Clin Oncol 33, 
2015 (suppl; abstr 9000)
Association of type and location of BRCA1 and 
BRCA2 mutations with risk of breast and ovarian 
cancer
Rebbeck TR, et al: JAMA 
313:1347-1361, 2015
Tumor biology Combined hereditary and somatic mutations of 
replication error repair genes result in rapid onset of 
ultra-hypermutated cancers
Shlien A, et al: Nat Genet 
47:257-62, 2015
Integrative clinical genomics of advanced prostate 
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Fig 1. 
Sustained robust federal funding critical to cancer progress.
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Fig 2. 
Immune checkpoint inhibitors: releasing the brakes on the immune system. Immune 
checkpoints function like brakes on the immune system, controlling the strength and 
duration of immune responses. MHC, major histocompatibility complex; PD-L1, 
programmed death-ligand 1; TCR, T-cell receptor.
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Table 1
FDA Approvals of Anticancer Therapies From October 2014 to October 2015
Drug Indication Date
New approvals
 Blinatumomab (Blincyto) Philadelphia chromosome–negative relapsed or refractory B-cell precursor 
ALL
December 2014
 Olaparib capsules (Lynparza) Deleterious or suspected deleterious germline BRCA-mutated advanced 
ovarian cancer treated with three or more prior lines of chemotherapy
December 2014
 Nivolumab (Opdivo) Unresectable or metastatic melanoma and disease progression after 
ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor
December 2014
 PV 9-valent vaccine (Gardasil 9) Prevention of certain cervical, vulvar, vaginal, and anal cancers caused by nine 
types of HPV (five more HPV types than Gardasil, previously approved by the 
FDA)
December 2014
 Palbociclib (Ibrance) In combination with letrozole for the treatment of postmenopausal women 
with ER-positive, HER2-negative advanced breast cancer as initial endocrine-
based therapy for metastatic disease
February 2015
 Lenvatinib (Lenvima) Locally recurrent or metastatic, progressive, radioactive iodine-refractory 
differentiated thyroid cancer
February 2015
 Panobinostat (Farydak capsules) In combination with bortezomib and dexamethasone for multiple myeloma 
treated with two or more prior regimens
February 2015
 Dinutuximab (Unituxin) In combination with GM-CSF, IL-2, and 13-cis-retinoic acid for pediatric 
patients with high-risk neuroblastoma who achieve at least a partial response 
to prior first-line multiagent, multimodality therapy
March 2015
 Sonidegib (Odomzo capsules) Locally advanced BCC that has recurred after surgery or radiation therapy, or 
for those who are not candidates for surgery or radiation therapy
July 2015
 Trifluridine/tipiracil (Lonsurf) mCRC previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-
based chemotherapy, an anti-VEGF biologic product, and an anti-EGFR 
monoclonal antibody, if RAS wild type
September 2015
 Trabectedin (Yondelis) Specific soft tissue sarcomas (liposarcoma and leiomyosarcoma) that cannot 
be removed by surgery (unresectable) or are advanced (metastatic) and 
previously treated with chemotherapy that contained anthracycline
October 2015
New uses
 Ramucirumab (Cyramza) In combination with paclitaxel for advanced gastric or GEJ adenocarcinoma November 2014
 Bevacizumab solution for intravenous 
infusion (Avastin)
In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan 
for platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary 
peritoneal cancer
November 2014
 Ramucirumab (Cyramza injection) In combination with docetaxel for metastatic NSCLC with disease progression 
on or after platinum-based chemotherapy
December 2014
 Ruxolitinib (Jakafi) PV for patients who have had an inadequate response to or are intolerant of 
hydroxyurea
December 2014
 Lanreotide (Somatuline depot 
injection)
Unresectable, well or moderately differentiated, locally advanced, or 
metastatic GEP-NETs to improve PFS
December 2014
 Ibrutinib (Imbruvica capsules) Waldenström’s macroglobulinemia January 2015
 Nivolumab (Opdivo) Metastatic squamous NSCLC with progression on or after platinum-based 
chemotherapy
March 2015
 Ramucirumab (Cyramza) In combination with FOLFIRI for mCRC when the disease has progressed 
during first-line bevacizumab-, oxaliplatin-, and fluoropyrimidine-containing 
regimen
April 2015
 Gefitinib (Iressa) Metastatic NSCLC when tumors have EGFR exon 19 deletions or exon 21 
(L858R) substitution mutations
July 2015
 Carfilzomib (Kyprolis) In combination with lenalidomide and dexamethasone for relapsed multiple 
myeloma treated with one to three prior lines of therapy
July 2015
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Drug Indication Date
 Nivolumab (Opdivo) In combination with ipilimumab for BRAF V600 wild-type, unresectable, or 
metastatic melanoma
September 2015
 Pembrolizumab (Keytruda) Advanced (metastatic) NSCLC that has progressed after other treatments and 
with tumors that express PD-L1
October 2015
 Tumor-treating fields device (Optune) Newly diagnosed glioblastoma multiforme October 2015
Abbreviations: ALL, acute lymphoblastic leukemia; BCC, basal cell carcinoma; EGFR, epidermal growth factor receptor; ER, estrogen receptor; 
FDA, US Food and Drug Administration; GEJ, gastroesophageal junction; GEP-NET, gastroenteropancreatic neuroendocrine tumor; GM-CSF, 
granulocyte-macrophage colony-stimulating factor; HER2, human epidermal growth factor receptor 2; HPV, human papillomavirus; IL-2, 
interleukin-2; mCRC, metastatic colorectal cancer; NSCLC, non–small-cell lung cancer; PD-L1, programmed death-ligand 1; PFS, progression-
free survival; PV, polycythemia vera; VEGF, vascular endothelial growth factor
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Table 2
ASCO Clinical Practice Guidelines, Endorsements, and Provisional Clinical Opinions From January to 
October 2015
Publication Date Title
Guidelines
 July 20, 2015 Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: 
American Society of Clinical Oncology Clinical Practice Guideline
Guideline updates
 January 20, 2015 Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical 
Oncology Clinical Practice Guideline Update 2014
 July 13, 2015 Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical 
Practice Guideline Update
 August 31, 2015 Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical 
Practice Guideline Update
Guideline endorsements
 February 9, 2015 Prostate Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice 
Guideline Endorsement
 May 5, 2015 Definitive and Adjuvant Radiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: American Society of 
Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology 
Evidence-Based Clinical Practice Guideline
 July 6, 2015 Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical 
Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline
 September 8, 2015 Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American 
College of Chest Physicians Guideline
Provisional clinical opinions
 October 5, 2015 Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–
Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology 
Provisional Clinical Opinion Update
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